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The fourth “Melanoma Bridge Meeting” took place in Naples, December 5 to 8th, 2013. The four topics discussed
at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in
Immunotherapy, and Tumor Microenvironment and Biomarkers.
Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent research in tumor
biology and immunology has led to the development of new targeted and immunotherapeutic agents that
prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein
kinase (MAPK) pathway inhibitors, like BRAF and MEK inhibitors, as well as other signaling pathways inhibitors, are
being tested in metastatic melanoma either as monotherapy or in combination, and have yielded promising results.
Improved survival rates have also been observed with immune therapy for patients with metastatic melanoma.
Immune-modulating antibodies came to the forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1
ligand 1 (PD-L1) pathway blocking antibodies that result in durable responses in a subset of melanoma patients.
Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors and other
approaches such as adoptive cell transfer demonstrate clinical benefit in melanoma as well.
This meeting’s specific focus was on advances in targeted therapy and immunotherapy. Both combination targeted
therapy approaches and different immunotherapies were discussed. Similarly to the previous meetings, the
importance of biomarkers for clinical application as markers for diagnosis, prognosis and prediction of treatment
response was an integral part of the meeting. Significant consideration was given to issues surrounding the
development of novel therapeutic targets as further study of patterns of resistance to both immunologic and
targeted drugs are paramount to future drug development to guide existing and future therapies. The overall
emphasis on biomarkers supports novel concepts toward integrating biomarkers into contemporary clinical
management of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge
gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on
prognosis and response to therapy in melanoma.* Correspondence: paolo.ascierto@gmail.com; thurinm@mail.nih.gov
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The Melanoma Bridge 2013 meeting began on December
5th, 2013 by acknowledging the recent passing of Professor
Natale Cascinelli by the organizers and all participants
(Figure 1). Professor Cascinelli was one of the best known
experts in melanoma in Europe. He was a scientific
director of the National Institute of Oncology in Milan
and was an active member of the Italian Ministry of
Health, World Health Organization and Alliance against
cancer among others.
Until 2011, dacarbazine (DTIC), interleukin (IL)-2 and
interferon (IFN)α-2b were the only Food and Drug
Administration (FDA) approved agents for the treatment
of metastatic melanoma. Other single chemotherapy agents
or angiogenesis inhibitors and combinations demonstrated
modest activities. However, a true breakthrough in treat-
ment of melanoma patients was the publication of the
results from the phase 3 randomized trials of ipilimumab
[1] and vemurafenib [2]. These trials demonstrated for
the first time the benefit for melanoma patients as the
treatment significantly improved overall survival (OS)
and progression free survival (PFS) as compared with
patients receiving chemotherapy in the control arms.
Both vemurafenib and ipilimumab were FDA approved
in 2011 and were added to dacarbazine and fotemustine
(in Europe), as standard therapies available for metastatic
melanoma patients.
The mitogen-activated protein kinase (MAPK) cascade
is a critical intracellular signaling pathway that regulates
cellular functions including proliferation, cell cycle regu-
lation, survival, angiogenesis, and cell migration. The
fundamental role of the RAS/RAF/MEK/ERK MAPK
pathway in these cellular functions underlies its import-
ance in oncogenesis and growth of melanoma cells [3].
Activating mutations in serine–threonine protein kinase
BRAF, a constituent of the MAP kinase signal transduction
pathway, have been identified in about 50% of patients with
advanced melanoma [4]. The most commonly observedFigure 1 Faculty and attendees of the 2013 Melanoma Bridge
Meeting in Naples.BRAF V600E mutation accounts for 90% of the mutations
found in all patients with cutaneous melanoma, while
other mutations (e.g., V600K, V600D, etc.) account for
the remaining 10%. Mutated BRAF phosphorylates and
activates MEK proteins (MEK1 and MEK2) which then
activate downstream MAP kinases cascade. Mutated
BRAF is the target of vemurafenib, a small molecule
that inhibits the signal transmission between BRAF and
MEK within the MAP-kinases pathway. This drug results
in dramatic responses with a rapid improvement of symp-
toms and performance status following a decrease in
metabolic rate and reduction of tumor size. The BRIM-3
trial, a phase 3 trial of vemurafenib vs. dacarbazine as
first-line therapy for BRAF-mutated metastatic melanoma,
demonstrated the advantage in OS of the targeted therapy
vs. the chemotherapy with respect to overall survival (13.2
vs. 9.2 months). Most frequent toxicities of vemurafenib
that patients experience include arthralgia, cutaneous
rash, photosensitivity reaction, and squamous cell car-
cinoma/keratoacanthoma that are observed in 26% of
patients [2].
Several new agents targeting BRAF and other down-
stream molecules in the RAS/RAF/MEK/ERK pathway
are being tested in the clinic as single agents and in
combination. Dabrafenib (Tafinlar) was FDA approved
in 2013 for treatment of melanoma patients with BRAF
V600E or V600K mutations. Dabrafenib seems also to be
quite effective in the treatment of intracranial metasta-
ses [5]. Selective MEK inhibitors inhibited growth and
induced cell death in BRAF mutated melanoma cell lines
[6]. Trametininb (Mekinist), a potent MEK1/2 inhibitor
received FDA approval in 2013 for treatment of patients
with metastatic melanoma harboring BRAF V600E/K
mutations. In Phase 3 clinical trial METRIC, patients were
assigned to receive either trametinib or chemotherapy
(decarbazine or paclitaxel). Patients treated with trameti-
nib demonstrated significant improvement in PFS and OS.
Currently, trametinib is not indicated for patients who
have received previous BRAF inhibitor therapy.
NRAS mutations are observed in 15–25% of melanomas
and are mutually exclusive with BRAF mutations; the
latter of which are reported in 40–60% of patients with
cutaneous melanoma [7,8]. BRAF and NRAS mutations
both activate downstream MEK kinase that serves as
the gatekeeper of extracellular signal-regulated kinase
(ERK) activation. MEK inhibitor (MEKi) confers a pref-
erential sensitivity to MEK kinase and thus it is a highly
attractive target for melanoma treatment, as majority of
tumors have mutations in either RAS (K-, N- or H-) or
BRAF.
The combination of the BRAF inhibitor dabrafenib
and the MEK inhibitor trametinib has been designed to
delay the development of resistance to treatment with
BRAF inhibitor (BRAFi), and to minimize toxic effects
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the phase 2 randomized trial of the combination of
dabrafenib and trametinib have been published [9]. The
data showed an important advantage of the combination
in PFS vs. dabrafenib alone with 9.4 vs. 5.8 months,
respectively. It received accelerated FDA approval in
2014 for use in the treatment of patients with metastatic
melanoma with BRAF V600E and V600K mutations.
Phase 3 randomized controlled trials comparing dabra-
fenib plus trametinib with dabrafenib or vemurafenib
are ongoing. Depending on the results from these trials,
the combination treatment might prove to be more
favorable as compared to monotherapy with BRAF and
MEK targeting agents. Studies comparing combinations
of other BRAF and MEK inhibitors in phase 3 trials are
also ongoing. At the 2013 ESMO/ECCO congress the data
regarding the combination of vemurafenib and cobime-
tinib (MEK inhibitor) were presented [10]. These data
demonstrated 85% objective responses (10% complete
responses, 75% partial responses in metastatic BRAF-
mutated melanoma), 13% stable disease and 2% progressive
disease, while at a median follow up of 10 months median
PFS was still not reached. A third combination of a BRAF
inhibitor and a MEK inhibitor, LGX818 plus MEK162
was presented at the 2013 ASCO Congress with very
encouraging preliminary data in BRAF-naïve and pre-
treated patients [11].
In the recent years, the blockade of immune check-
points gained attention as one of the most promising
approaches to activate anti-tumor immunity. Antigen
presentation to T cells involves contact between T cell
receptor (TCR) on T lymphocytes (TCL) and MHC of the
Antigen Presenting Cells (APC). In addition, to activate
the immune response binding between ligands B7-1 or
B7-2 on APC and the co-stimulatory receptor CD-28 on
TCL is required. To avoid excessive or auto immune T cell
responses receptors that inhibit the immune response
including cytotoxic T-lymphocyte associated antigen-4
(CTLA-4), are expressed on the T cell surface. Thus,
targeting inhibitory immune receptors on activated T cells
seems to be a logical approach to activate host immune
response. Monoclonal antibodies (MAbs) targeting T cell
checkpoint receptors such as CTLA-4, programmed cell
death-1 (PD-1) receptor and others have shown great
promise against advanced melanoma as well as lung and
kidney cancers. Ipilimumab and tremelimumab are fully
humanized MAbs targeting CTLA-4 receptor. Blocking of
CTLA-4 results in enhancement of immune responses
that are dependent on CD8+ effector T cells and CD4+ T
cells, and inhibition of the suppressive function of T
regulatory cells (Tregs). Phase 3 clinical trial comparing
combination of ipilimumab plus gp100 glycoprotein
vaccine vs. ipilimumab and the vaccine alone resulted
in 1-year survival of 43.6%, 45.6%, and 25.3% patients,respectively. Two-year survival rates were 21.6% among
patients who received combination therapy, 23.5% who
received ipilimumab alone, and 13.7% among those
who received gp100 alone [1]. Toxicity of ipilimumab is
immune-mediated and most frequent side effects result
diarrhea, pruritus, and, less frequently endocrinopathies
and autoimmune hepatitis.
PD-1 is another inhibitory receptor on activated and
exhausted T cells. Its two ligands PD-L1 and PD-L2 have
distinct expression profiles. PD-L1 is expressed on a variety
of immune and non-immune cells including various
tumor types while PD-L2 is mainly expressed on antigen
presenting cells. Blocking of the PD-1/PD-L1 interaction
by administration of anti-PD-1 or anti-PD-L1 MAbs can
activate T cells and enhance adaptive anti-tumor immune
responses. Nivolumab [12] and MK-3475 (pembrolizumab
formerly lambrolizumab) [13] are humanized MAb that
block the interaction between PD-1 and its ligands and
demonstrate durable responses in patients with advanced
melanoma. As monotherapy MK3475 and nivolumab
resulted in 37% and 31% objective response rate (ORR),
respectively. In nivolumab-treated patients, 1 and 2 year
survival was observed in 62% and 43% patients, respect-
ively. Furthermore, the phase 1 trial of the combination
of ipilimumab and nivolumab [14] demonstrated 40%
ORR that can be compared to the ORR with vemurafenib
(53%) and an estimated 1 year survival rate 82% in BRAF
mutated patients. A phase 3 trial comparing concurrent
nivolumab plus ipilimumab vs. either agent alone has
been activated and is recruiting patients (NCT01844505).
Pembrolizumab (Keytruda) received recently (2014) FDA
approval for patients with unresectable or metastatic mel-
anoma and nivolumab is expected to be approved by the
FDA as soon as recent trial results are mature. In addition,
treatment with anti-PD-L1 antibodies (e.g., MPDL 3280A
and BMS-936559) was associated with durable responses
with manageable toxic effects [15,16]. Overall, PD-1/PD-
L1 blocking agents have shown an overall higher RR than
ipilimumab and represent highly promising therapeutic
options for melanoma patients.
Adoptive Cell Transfer therapy (ACT) yielded promis-
ing results in patients with variety of cancers including
melanoma. There are many forms of ACT therapies being
developed and sufficient amount of data demonstrate that
expanded tumor infiltrating cells (TILs) or genetically
engineered lymphocytes recognizing specific tumor can
have potent, long-lasting effect-and can even eradicate
some tumors entirely. One approach to immunotherapy
involves patients’ own immune cells that recognize and
attack their tumors. Although this approach has been
restricted to small clinical trials so far, treatments using
TILs have generated remarkable responses in patients
with advanced cancer [17]. Lymphocytes can also be
genetically engineered using viral vectors to produce
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antigen receptors (CARs). CARs are proteins that allow
the T cells to recognize a specific antigen on tumor
cells. Other approaches focus on TCR modified ACT
therapy that involves introducing new TCR receptors
that allow them to recognize specific cancer antigens.
Both CAR and TCR therapies are being tested in
patients with a variety of cancers and move closer to
the mainstream; the next step will be investigating
whether and how to integrate them with other cancer
immunotherapies [18].
In summary, in just over 2 years, several agents have
demonstrated an overall survival advantage for the
treatment of patients with metastatic melanoma. Several
drugs have been approved for the treatment of advanced
melanoma and new class of agents has recently been
shown to lead to durable responses in a substantial
number of patients. There are now five categories of
FDA-approved agents for these patients, including
chemotherapy (dacarbazine), cytokines (IL-2 and IFNα),
targeted therapy drugs including BRAF inhibitors (dab-
rafenib, vemurafenib) and MEK inhibitor (trametinib),
immunotherapy agents anti-CTLA-4 (ipilimumab) and
anti-PD-1 (pembrolizumab) MAbs, and the combination
(dabrafenib and trametinib). In the coming years, it is
reasonable to expect that another MEK inhibitor
(MEK162), a third BRAF inhibitor (LGX818), another
anti-PD-1 antibody (nivolumab) and an anti-PD-L1
antibody (MPDL3280A) will join the ranks of approved
agents in melanoma.
Critical areas requiring rapid progress include efficiently
combining the “best in class” drugs that already have
demonstrated single-agent activity rather than multipli-
cation of trials using drugs of the same classes. For
example, vemurafenib and ipilimumab are drugs with
different mechanisms of action and different kinetics of
response: vemurafenib demonstrates quick action with
rapid metabolic shutdown but with a response lasting
only 6–8 months while ipilimumab acts slowly but is able
to stabilize the disease. Thus, there is a strong rationale to
consider immunotherapy in combination with molecularly
targeted therapy for melanoma. Combinations that include
immune checkpoint inhibitors and targeted therapy drugs
are testing this hypothesis in clinic. While more work is
required to achieve the goal of treating patients with
regimens that are associated with durable remissions in
the great majority of patients, there is hope that this
goal will be achieved in the relatively near future.
Diagnosis and new procedures
Established biomarkers for melanoma include the mor-
phological and histopathological characteristics of the pri-
mary tumor. However, prognosis and risk for recurrence
at any stage is only partially explained by parameters suchas primary tumor localization, patient gender and age,
mitotic rate, tumor thickness and ulceration. The patho-
logical diagnosis of melanoma can be difficult as no single
histological attribute can reliably be utilized to distin-
guish between nevus, borderline lesions and melanoma.
In addition, the clinical heterogeneity of melanoma requires
the development of classification schemes that use different
factors to capture the various subtypes of melanoma. This
ongoing process of tissue as well as serum biomarker
identification and validation is resulting in a rapidly
changing molecular view of cutaneous melanoma, which
holds the promise of improving diagnostic and prognostic
classification systems. However, significant challenges still
remain to optimize and validate the molecular diagnostics
for melanoma.
Five to ten per cent of individuals with melanoma have
a family history of melanoma. In families with melanoma,
affected individuals often have the atypical mole syn-
drome phenotype. About a quarter of all families with a
hereditary pattern of melanoma have been linked to
mutations in the tumor suppressor gene CDKN2A/p16
on chromosome 9p21, which affects the germline DNA
and is therefore transmitted through generations. The
p16 mutation carriers have exceptional risk to develop
a melanoma, and the environment is likely to modify risk
in p16 mutation carriers. CDKN2A/p16 has different
penetrance depending on the geographical environment,
ranging from 58% in the United Kingdom to 76% in the
USA, and 91-92% in Australia [19]. Unfortunately, com-
pliance with prevention recommendations is poor in this
high-risk population, despite education, though it has
recently been shown that p16 mutation carriers increase
compliance with photo protection, self-skin examinations,
and screening examinations following receipt of genetic
counseling and genetic test results [20-21]. A study report-
ing the effects of melanoma genetic counseling and test
reporting on screening adherence among unaffected
carriers two years later has been recently published
[22]. The population of this trial was composed by two
large p16 mutated families, divided in 3 study groups
(Unaffected non-carriers, Unaffected carriers and Affected
carriers) with adherence reports obtained at baseline prior
to reporting, immediately following test reporting, and
at 1 month, 6 month, 1 year and 2 year time points to
evaluate the long-range impact on prevention and
screening. Unaffected carriers had durable improvement
in the use protective clothing at 2 years and similar
improvements were observed in daily routine use of
photo protection and reduction of sunburns. In this
population group even an improvement in Total Body
Skin Examinations (TBSEs) was observed, especially com-
pared with affected carriers. Similar improvements were
reported for the number of Self Skin Examination (SSEs)
and sites of SSEs at 2 years. So this study concluded that
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compliance with some, but not all prevention recommen-
dations and unaffected p16 carriers have the most to
gain and demonstrate the most dramatic effect. It is
not clear why provision of a personalized genetic result
might empower behavioral change more than counseling
alone.
In patients with excised cutaneous melanoma (CMM)
appropriate follow-up testing has a higher impact on
survival than adjuvant treatment. Lymph node (LN)
ultrasound and protein S100ß levels in the peripheral
blood are the key examinations. PET-CT demonstrated to
be superior to conventional CT in detecting new meta-
static lesions. The percent of patients with recurrences
correlates with clinical stage, ranging from 0.4% for
patients with stage IA to 30.3% for patients with stage
IIIB melanoma. Recurrences can be considered “early”
when the lesions are no more than 2 cm in diameter
and there are less than 10 nodules that are totally surgi-
cally removable. “Late” recurrences are all other kind of
metastases including LN, in transit, visceral etc. Overall
survival of patients with recurrences vary depending on
the early or late recurrence, and is more favorable for
the first group. Survival benefit partially depends on the
earlier time point of diagnosis and a resulting longer
observation period between diagnosis and subsequent
relapse or death (29.4% vs. 15.9% patients alive after
recurrence at a median follow-up of more than 70 months
in early and late recurrence groups, respectively). In a
prospective study in 1288 melanoma patients, palpation
of subcutaneous lymph nodes gave false-negative results
in 68 of the 238 cases of histopathologically proven metas-
tases (28.6%) [23]. Clinical examination was the least
sensitive in the supraclavicular, axillary, and infraclavi-
cular regions. The sensitivity and specificity of ultrasound
examination were 89.2% and 99.7%, respectively, and
clinical examination was determined to be 71.4% sensitive
and 99.7% specific. Lymph node ultrasound recognizes
1/3 of lymph nodal metastases earlier than palpation
and is recommended in stages IB – IIIC. Thus, the staging
of primary melanoma for stage IA (≤1 mm) patients
should be performed by physical examination (palpation)
and dermoscopy, while for stage IB – IIB should include
physical examination (palpation), dermoscopy, lymph node
ultrasound and detection of protein S100ß in peripheral
blood. For stage IIC – IIIC melanoma patients staging
should be performed by physical examination (palpation),
dermoscopy, lymph node ultrasound, detection of protein
S100ß in peripheral blood, brain MRI and PET-CT scan or
whole body CT scan.
Many serum biomarkers have been evaluated in CMM
and several proteins and gene expression levels can be
considered as potential biomarkers [24]. However, they
remain to be clinically validated in order to provide therationale for diagnosis, prognosis and the follow-up.
Serum levels of Lactate dehydrogenase (LDH), Alkaline
phosphatase (AP), and Melanoma Inhibitory Activity
(MIA) as well as Tyrosinase (Tyr) and MelanA/Mart1
detected by RT-PCR have been shown to correlate with
clinical stage and tumor progression. Protein S100ß at
the cut off value of 0.12 μg/dl has a diagnostic accuracy
of 0.84 (0.29 sensitivity – 0.93 specificity), MIA at the
cut off value of 10.49 ng/dl has a diagnostic accuracy of
0.86 (0.22 sensitivity – 0.97 specificity), LDH at the cut
off value of 240 U/L has a diagnostic accuracy of 0.77
(0.02 sensitivity – 0.90 specificity), AP at the cut off
value of 168 IU/L has a diagnostic accuracy of 0.79
(0.17 sensitivity – 0.89 specificity) and RT-PCR (at the
cutoff for Positive/Negative) has a diagnostic accuracy
of 0.72 (0.24 sensitivity – 0.80 specificity). S100ß has been
considered prognostic marker in metastatic melanoma as
it is more related to the tumor burden and thus reflects
both clinical stage and tumor progression. Although it
seems to be limited to advanced stage III and stage IV
melanoma patients and does not provide independent
prognostic information it has become the most useful
melanoma marker in clinical practice. Combining the
prognostic value of LDH and S100ß it is possible to create
4 groups of melanoma patients with different prognosis
and risk for relapse.
Detection of first relapse in stage III melanoma changes
depends on the site of metastasis. Systemic metastasis are
discovered in 53% of patients with the imaging exams,
while nodal and local/in transit relapses are detected by
the patients or their families in 48.6 and 62.5%, respect-
ively. Several recommendations for follow-up schedules
have been issued in Germany since 1990s regarding the
length of the follow-up for melanoma patients but it
did not reach international consensus. A recommendation
of 10-years risk adapted follow-up with reduction of
frequency of visits in the course of observation was
recommended by some authors, while a long-term or
lifelong follow-up based on risk of development of
secondary CM has been proposed by others. An intense
follow-up should be performed in the first 3 years post
diagnosis as 80% of the recurrences occur in this period.
Regular follow-up can be completed at 10 years. In patients
with individual risk factors (dysplastic nevus syndrome,
history of familial melanoma) dermatologic examinations
should be performed lifelong. For stage IA follow-up visits
should be performed every 6 months for the first 3 years
and yearly until the completion at 10 years. Stage IB – IIB
patients should be examined every 3 months for the
first 3 years, every 6 months for the next 2 years and
yearly until the completion at 10 years. For stage IIC – IV
melanoma patients, follow-up visits should be performed
every 3 months for the first 6 years and every 6 months
until the completion at 10 years [25].
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diagnosis of secondary melanomas is the goal of follow-up
examinations, because this has an impact on overall
survival of the patients. Frequency and scale of surveil-
lance examinations should be adapted to the stage of
the disease. In patients with medium risk for recurrence
lymph node ultrasound and protein S100ß levels are
recommended while in stage III patients regular imaging
examinations are more appropriate.
For classic melanocytic lesions histological diagnosis
is very accurate (>97%). Real problems begin with border-
line lesions as melanocytic tumors of unknown malignant
potential (MELTUMPs), atypical nevoid and spitzoid
lesions, atypical cellular blue nevi, deep penetrating nevi,
pigmented epithelioid melanocytomas etc. Predicting
the biology of borderline lesions is difficult and may be
incorrect and confound therapy, so adjunctive techniques
are required accurately to diagnose such lesions and allow
a better understanding of their etiology and relationships.
To better understand the differences between borderline
lesions Gene Expression Micro-arrays (GEM) can be used.
This technique is performed by micro-dissection of the
sample to separate tumor from normal non-tumorous
tissue. Total mRNA is isolated, amplified and labeled
before hybridization to human gene chip arrays to seek
differentially expressed genes (>/=x 2 difference of gene
expression in subgroups at p < 0.05 level of significance).
Differential gene expression profile for primary melanoma
and melanoma metastatic to sentinel lymph nodes using
DNA micro array technology has been studied [26]. Genes
involved in melanoma progression and early (lymphatic)
metastases have been analyzed to identify gene markers
with potential for prediction of prognosis, therapeutics,
and diagnostics. A significantly lower level of gene expres-
sion was observed in metastases. e.g., Sentinel LN (SLN)
metastases had fewer “up-regulated” genes relative to pri-
mary cutaneous melanoma. “Up regulated” genes showed
less significant fold-change than “down- regulated” genes.
Decreased gene products included encoded protein
products involved in cell adhesion, cellular structural
integrity and tumor suppression (e.g., Gap junction pro-
teins, keratins, and stratifin), while MAGE proteins showed
increased expression in SLN metastases. A non-protein
coding nuclear RNA product of XIST was also increased in
the metastases. Information gained in this study may help
to understand the molecular events that underpin lymph-
atic invasion and the development of nodal metastases and
may lead to biomarkers to identify primary lesions with the
potential for lymphatic extension. Increased understanding
of the molecular mechanisms of melanoma progression will
contribute to improvements in treatment, diagnosis, and
prognostic prediction.
Another ongoing project showed differential gene
expression in the sentinel node that was predictive ofnon-sentinel node tumor status [Huang et al. in prepar-
ation]. SNL biopsy is widely used in the management of
patients with melanoma. Results of the MSLT2 trial are
still pending, and all patients with SN metastases are
currently offered immediate completion lymph node
dissection (CLND). However, not all patients with SN
metastases will gain benefit from immediate CLND. So
the problem is to identify patients likely to benefit from
early nodal surgery. GEM has been used to investigate
metastatic melanoma in SN from 15 patients who had
immediate CLND: 7 with no melanoma in non-sentinel
nodes (NSN) and 8 with metastasis-positive NSN. Signifi-
cantly different levels in expression of 1232 genes have
been found comparing these two groups. Combination of
gene signatures, with clinical-pathological features, can
enhance accuracy of prediction of NSN tumor status,
separating patients likely to benefit from CLND, from
those unlikely to so benefit. This has the potential to spare
many patients the morbidity of unnecessary additional
surgery and significantly reduce costs and post-surgery
side effects, with improvement in quality of life. In future,
enhanced staging will identify patients at high risk of vis-
ceral metastases who may benefit from adjuvant therapy.
GEM has also been used to compare conventional
melanoma (cMM), nevoid melanoma (NM) and benign
atypical nevi (BAN) [Sarantopoulos et al. in preparation].
Nevoid melanoma (NM) is a melanoma (MM) variant
that mimics atypical nevi (AN) clinically and microscop-
ically. Characteristics of NM can be very subtle and NM
carries a high potential for misdiagnosis, treatment delay
and medical and legal consequences. Currently, no tests
exist that help differentiate atypical or “borderline” nevoid
melanocytic lesions from nevoid melanoma. This study
attempts to distinguish NM from AN and MM using
gene micro array technology. Results of this study are
expected to lead to development of novel molecular tests
to separate these morphologically similar, but clinically
disparate lesions. Although some commonality exists
between nevoid and conventional melanomas discrete
clustering of genes in NM relative to AN and MM
suggests a distinctive molecular pathobiology for NM.
One case of AN fell into NM’s gene expression territory
on principle component analysis (PCA). Close histological
examination of this outlier case did not show evidence of
malignancy or changes suggestive of nevoid melanoma.
The question whether this lesion is a potential pre-cursor
to NM will only be settled by further investigation and
clinical follow-up.
A further project is studying GEM Signatures of Spit-
zoid Lesions [Hillman et al. in progress]. These studies
seek to determine whether there are genetic differences
between Spitz nevus, spitzoid melanoma and atypical
spitzoid tumors. Other questions are whether these
genetic differences underpin the differing biology of these
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to be used as an adjunct to histology in separating these
lesions. It may be possible to separate at least some
spitzoid melanomas and some lesions diagnosed micro-
scopically as either Spitz nevus or atypical spitzoid lesion
vs. spitzoid melanoma using GEM to supplement clinical
and microscopic examination. Further studies with clinical
follow-up are needed to correlate differences in gene
expression with clinical behavior in spitzoid melanoma
and SM and other spitzoid lesions.
The 7th edition of the AJCC melanoma staging system
presented no major recommended changes for TNM
and stage grouping criteria [27]. Mitotic rate was identi-
fied as an independent prognostic factor (patients with
T1 melanoma included in T1b if at least 1 mitosis/mm2)
and immunohistochemical detection of nodal metastases
is also considered acceptable without a lower limit to
designate N + disease. Stage IV analysis included more
than 9900 patients and the overall revisions were approved
by the UICC. The importance of mitotic rate as a prognos-
tic factor for survival in stages I/II melanoma patients
emerged from the analyses of the 2008 AJCC collaborative
melanoma database. Moreover, in the 6th edition of the
AJCC melanoma staging system, stratification between
T1a and T1b was based on ulceration and Clark level,
while in the 7th edition, stratification of patients with
T1 melanoma is based on ulceration and number of
mitoses/mm2 (≥1 vs <1). Evidence from multivariate sur-
vival analyses of patients with AJCC stages I/II melanoma
showed that mitotic rate was the 2nd most powerful inde-
pendent predictor of survival after tumor thickness [28].
In another study, age was shown to be an independent
predictor of survival for stages I, II and III melanoma;
mitotic rate emerged as an independent predictor of
survival except in patients <20 yrs and >70 yrs [29,30].
AJCC recommendations for N-staging included micro
staging of all primary melanomas and pathological nodal
staging for TIb-TIIc melanoma (since 2002) to minimize
prognostic heterogeneity within stages and to incorporate
SLN assessment into the staging system. The stratification
of T1 disease into T1a and T1b melanoma continues to
evolve. The technique of lymphatic mapping and sentinel
lymph node biopsy has revolutionized the staging of
melanoma [31]. The paradigm of nodal involvement has
changed from macroscopic lymph node involvement to
microscopic involvement with the implementation of
lymphatic mapping and sentinel lymph node biopsy into
treatment paradigms for patients with early-stage melan-
oma who are at risk for regional lymph node metastasis.
Important prognostic factors among patients with regional
node disease (stage III) include tumor burden, number of
involved regional nodes, and primary tumor ulceration
[27-32]. In a multivariate analysis for stage III melanoma
patients with microscopic regional node involvement,important predictors of survival included the number
of positive lymph nodes, tumor thickness, primary
tumor ulceration, age, site of primary tumor, sex, and
mitotic rate, while in patients with macroscopic involve-
ment only number of positive lymph nodes and age were
significant [32].
Despite tremendous strides in melanoma staging (e.g.,
AJCC/UICC), limitations exist in traditional staging systems
regarding the ability to integrate various characteristics
(patient, tumor, etc.), the inability to use continuous
variables, and that estimates of survival are based only
on time of diagnosis. Moreover, TNM-based staging
generally applies to large cohorts of patients (and is
therefore not truly individualized). To improve melanoma
staging and prognosis, new statistical models and contem-
porary analytic approaches can be leveraged that better
inform the use of multiple characteristics and continuous
variables (such as mitotic rate, tumor thickness, or SLN
tumor burden) or that estimate conditional survival prob-
ability after treatment and at any time during follow-up.
Overall, this approach may significantly enhance our
ability to combine prognostic features to better estimate
cancer-specific survival in individual patient settings,
ultimately by also integrating clinicopathological factors
with molecular, immunological and/or host profiles [33].
Molecular Advances and combination therapies
A greater understanding of the molecular biology of
melanoma has guided much of the translational research
in this disease and has led to the development of novel
targeted therapies. Specifically, identification of alterations
in signal transduction pathways has led to the develop-
ment of a number of inhibitors of these pathways. Studies
are underway combining different targeted agents, as
well as combinations of immune therapy and signal
transduction inhibitors. However, there is a growing
concern over drug resistance to molecular therapies
including BRAF inhibitors. Thus, novel targets for the
treatment of metastatic melanoma are urgently needed.
Next generation sequencing (NGS) techniques for both
whole exome sequencing (WES) and whole genome
sequencing (WGS) have been used to characterize the
overall genomic landscape of melanomas. These studies
identify mutation signatures associated with melanomas
with the most common well characterized driver genes
e.g., BRAF, NRAS, KIT, GNAQ, or GNA11. In addition,
mutations that co-occur with the most common driver
mutations could contribute to disease progression. For
example, mutations in p53 and COL1A1 genes more
likely associate with BRAF whereas mutated PPP6C,
KALRN, PIK3R4, TRPM6, GUCY2C, and PRKAA2 were
found to be more frequently associated with NRAS
mutated melanomas. Other potential driver genes were
found in so called pan-negative melanomas that do not
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DGKI, RAC1, EPHA4, ADAMTS18, EPHA7, ERBB4,
TAF1L, NF1, SYK, and KDR [34].
Melanoma has a high prevalence of somatic mutations
with more than 700 described in literature. Mutated
“driver” genes confer growth advantage and are required
for maintenance of the cancer cells. In contrast, “passenger”
mutations do not confer clonal growth advantage and
therefore do not contribute to cancer development. How-
ever, they might be carried along in the clonal expansion
and therefore are present in all cancer cells. A central goal
of cancer genome analysis is the identification of cancer
genes that, by definition, carry driver mutations (oncogenes
and tumor suppressor genes). A key challenge will therefore
be to distinguish driver from passenger mutations. Exome
sequencing has been successfully used to characterize
mutational landscape of melanoma. Recently discovered
mutated genes have highlighted new pathways as potential
markers and therapeutic targets including RAC1 (RAS
related rho family, small GTP binding protein), Neuro-
fibromin 1 (NF1), and protein phosphatase 6 catalytic
subunit (PPP6C).
A recurrent somatic missense mutation in RAC1 at
the codon 29 that results in substitution of a proline to
a serine residue (RAC1P29S) was discovered in up to
9% of sun-exposed melanomas in the Yale cohort. This
discovery makes RAC1P29S the third recurrent most
commonly mutated proto-oncogene in melanoma after
BRAF and NRAS [35,36]. RAC1P29S is present in both
BRAF/NRAS mutated and wild type cutaneous melano-
mas. Furthermore, RAC1P29S mutation is predominant
in males (95%) and is associated with a signature of UVB
induced DNA damage CCT >TCT. Most patients in the
Yale cohort reported excess sun exposure and most of the
primary melanoma lesions were in sun exposed areas.
This mutation is not detected in congenital, benign or
blue nevi. It is not present in the germline DNA of
1,700 melanoma patients tested out of the sample of
5,090 individuals from USA and a worldwide. RAC1P29S
is the first recurrent, cancer-associated, gain-of-function
mutation belonging to the Rho-family GTPase. It is a
“fast-cycling” mutant, with increased inherent GDP→
GTP nucleotide exchange with no effect on GTPase
activity [37]. RAC1P29S displays increased binding to
target kinases PAK1 and MAP3K11 (MLK3), increases
membrane ruffling, cell proliferation and migration of
melanocytes. Since RAC1 promotes melanoma cell prolif-
eration this pathway can become a new target for therapy,
but preclinical data and clinical trials confirming its
clinical relevance are required.
The NF1 tumor suppressor gene encodes a RAS
GTPase-activating protein neurofibromin, which nega-
tively regulates RAS by catalyzing the hydrolysis of RAS-
GTP to RAS-GDP. Consequently, RAS and downstreameffector pathways can be aberrantly activated in NF1-defi-
cient tumors. Inactivating mutations are frequent in NF1
and are more common in sun-exposed melanoma in older
patients and in melanomas lacking BRAF/NRAS mutations
[35]. Importantly, loss of function NF1 gene mutations
can result in the sustained activation of the MAPK path-
way which may render cells resistant to RAF and MEK
inhibitors [38]. Together, these studies provide new insights
into the signaling that underlies melanoma initiation and
progression and suggest novel therapeutic strategies for
patients whose melanomas are NF1-deficient.
Mutations in the catalytic subunit of protein phosphat-
ase 6 (PPP6C) have been identified in ~12% of cutaneous
melanomas suggesting that it may act as a driver gene.
All mutations in PPP6C are in the active domain and
most are in tumors with BRAF/NRAS mutations. Protein
phosphatase 6 is reported to regulate NF-κB, DNA-
dependent protein kinase (DNA-PK), histone γ-H2AX,
and Aurora-A kinase. Mutations in PPP6C reduce phos-
phatase activity, leading to activation of oncogenic kinase
Aurora-A which is the major PP6 substrate, resulting in
chromosome instability and DNA damage [39]. This
suggests that inhibition of Aurora-A kinase activity may
be useful in the treatment of melanoma. Specific kinase
inhibitors targeting Aurora-A and B already demonstrated
promising results in clinical trials.
The power of high-throughput NGS such as exome
sequencing is being harnessed in addressing an increas-
ingly diverse range of biological problems including
tumor heterogeneity, drug resistance, neoantigens, new
markers and therapy targets.
The importance of the information generated through
this method is application of NGS for routine clinical se-
quencing for patient’s selection for specific treatments,
identification of resistance mechanism and designing al-
ternative therapies.
Since 2011 three selective BRAF inhibitors (BRAFi)
(vemurafenib, dabrafenib and LGX818) have been devel-
oped as monotherapy treatment and clinically tested in
combination with MEKi and other compounds in melan-
oma. As a single agent LGX818 in the phase 1 escalation
trial obtained disease control rates of 88% for BRAFi naïve
patients (65% overall response rate, ORR) and 43% for
patients previously treated with a BRAFi (11% ORR).
Median PFS was 217 days (about 7.1 months; 95% CI,
135- > 337 days) in BRAFi naïve patients and 58 days
(about 1.9 months) in patients previously treated with a
BRAFi. Median duration of response (DOR) was estimated
to be 45.3 weeks (95% CI, 17.1-not reached) for BRAFi
naïve patients and 16.1 weeks (95% CI, 13.9-19.1) for
BRAFi pretreated patients. Toxicity profile was favorable,
especially compared with the other BRAFi with very low
incidence of fever, arthralgia, photosensitivity reactions
whereas squamous cell carcinoma (SCC) \Plantar-Palmar
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of LGX818 [40].
However, the clinical use of BRAF inhibitors for treat-
ment of metastatic melanoma is limited by the develop-
ment of drug resistance. There are various mechanisms of
acquired (late) BRAFi resistance through MAPK pathway
reactivation such as BRAF amplification and alternative
splicing, RAS mutations, CDKN2A mutations, activating
mutations in MEK1/2 and NF1 loss [41]. Overexpression
of Ser/Thr kinase COT encoded by MAP3K8 gene has
also been described in the context of BRAF inhibitor
resistance. Almost all these mechanisms lead to reacti-
vation of MAPK pathway and dual inhibition of both
MEK and BRAF is thought to circumvent treatment
resistance that commonly occurs with single-agent therapy.
Recently, a potent MEK1/2 inhibitor trametininb was
developed for treatment of patients with unresectable
metastatic melanoma harboring BRAF V600E/K mutations
[42]. Another MEK inhibitor, MEK 162 is active in both in
BRAF mutated and NRAS mutated metastatic melanoma.
In phase 2 clinical trial MEK162 treatment resulted in a
PFS of 4.8 months with a favorable toxicity profile. The
most frequent toxicities have been in papulopustolar cuta-
neous rash, creatine phosphokinase (CPK) elevation, and
visual disturbances [43]. GDC-0973 (cobimetinib), another
MEK inhibitor was tested in previously untreated BRAF
V600 mutation-positive patients with unresectable locally
advanced or metastatic melanoma. Other clinical trials
with agents blocking oncogenic MAPK pathway signaling
include studies with two ERK 1 and 2 inhibitors, MK-8353
(formerly SCH 900353, Merck) and BVD-523 (BioMed
Valley Discoveries, Inc.).
In 2014 the FDA approved the combination of the
BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibi-
tor trametinib (Mekinist) for patients with unresectable
or metastatic melanoma who harbor a BRAF V600E or
V600K mutation [9]. In the phase 2 trial BRF113220 of
dabrafenib plus trametinib vs. dabrafenib alone, the
targeted therapy combination demonstrated a higher
response rate (76% vs. 54%, respectively). Patients pro-
gressing on dabrafenib could cross to the combination
arm (45 of 54 monotherapy treated subjects crossed-
over). Median PFS was 9.4 months for the combination
vs. 5.8 months for dabrafenib alone. Phase 3 ran-
domized controlled trials comparing dabrafenib plus
trametinib with dabrafenib (NCT01584648) or vemura-
fenib (NCT01597908) are ongoing.
Preclinical data in a model of BRAF mutant melanoma
also supported the combination of LGX818 and MEK162.
In the dose escalation phase the doses to be used in
the expansion phase of the combination of LGX818 at
600 mg and MEK162 at 45 mg were identified, according
to the dose limiting toxicity (DLTs). Both BRAFi naïve and
BRAFi pre-treated BRAF-mutated metastatic melanomapatients were enrolled [10]. PK profile of the combination
was similar to that of the two monotherapies on both
day 1 and day 15, no drug-drug interaction (DDI) was
observed and drug exposures were similar in combin-
ation compared with single-agent studies of MEK162
and LGX818. The overall response rate was 89% for
BRAFi-naïve and 21% for BRAFi-pretreated patients
with melanoma and 67% for patients with PTC. As of
July 1, 2013, 11 of 30 patients remained under study,
including 7 of 9 patients with BRAFi-naïve melanoma
(Range duration of exposure was 3.9-12.6 months), 3 of
14 patients with BRAFi-pretreated melanoma (Range
duration of exposure was 0.2-12.6 months) and 1 of 7
patients with mCRC or PTC. Toxicity profile was mild
and the only G.3 adverse event (AE) resulted in trans-
aminase elevation in 2 patients (6.7%). Compared with the
other two combinations LGX818 plus MEK162 were
much more tolerable for cutaneous, gastrointestinal and
hepatic side effects. Ocular toxicity rate was slightly higher
than that seen with the combinations of dabrafenib plus
trametinib and vemurafenib plus cobimetinib.
Another combination of vemurafenib and the MEK
inhibitor cobimetinib (GDC0973) was tested in the phase
2 BRIM-7 trial [9]. BRAF inhibitor naïve mutated meta-
static melanoma patients obtained 85% response rate with
a disease control rate of 98%. At a median follow-up time
of 10 months median (m) PFS was not reached, while in
patients who progressed with BRAFi the PFS resulted in
2.8 months. Phase 3 trial of cobimetinib in combination
with vemurafenib compared with vemurafenib alone in
melanoma that will evaluate the treatment efficacy in pre-
viously untreated BRAF V600 mutation-positive patients
with unresectable locally advanced or metastatic melan-
oma is ongoing (NCT01689519). The combination of
the BRAF inhibitor vemurafenib and the MEK inhibitor
cobimetinib significantly improved progression-free sur-
vival (PFS) compared with vemurafenib alone for patients
with untreated BRAFV600-mutated advanced melanoma,
according to the results from this study. Ninety nine
percent of the tumors that had a complete remission
with the BRAFi plus MEKi combination therapy will
never progress. Progression occurs in 50% of the cases
with new lesions, in 44% with the progression of pre-
existing lesions, and in 6% with both.
However, resistance is a concern even with the com-
bination of BRAFi plus MEKi treatment. Although, the
withdrawal of the drugs administration might result in a
rapid progression of the disease the potential strategy to
reduce side-effects and to prolong PFS could be an
intermittent dosing regimen. Intermittent therapy was
demonstrated to prevent the onset of the resistance to
BRAFi in a murine xenograft model [44]. A recent report
also demonstrated that melanoma patients who developed
resistance to dabrafenib or the combination of dabrafenib
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inhibition following treatment interruption [45]. Because
MAPK and PI3K-AKT pathways are the predominant
signaling pathways in melanoma and MAPK-independent
resistance to BRAF inhibitors can be mediated through
enhancement of signaling through the PI3K-AKT path-
way. Activation of the PI3K-AKT pathway can be achieved
by activating mutations in the signaling molecules,
deletion of the phosphatase and tensin homolog (PTEN)
or overexpression or over-activation of upstream receptor
tyrosine kinases (RTKs) including PDGFRβ, IGFR-1 or
EGFR. There are three distinct genes encoding unique
isoforms of AKT located at loci 14q32, 19q13, and 1q44,
encoding AKT1, AKT2 and AKT3, respectively. The three
isoforms of AKT may each have distinct biological
relevance which points to the need to selectively target
AKT isoforms in clinical drug development. Phosphoryl-
ation activates AKT, which then triggers a number of
downstream signals. Particularly relevant in cancer is
stimulation of tuberous sclerosis complex 2 (TSC2)
protein, which associates with tuberous sclerosis 1 (TSC1)
and is a key mediator of the mammalian target of rapamy-
cin (mTOR) [46]. Increased reliance on PI3-AKT pathway
as resistance mechanism to BRAF/MEK inhibition sug-
gests that co-targeting the MAPK and the PI3K-AKT
pathways would be reasonable approach to achieve
synergistic anti-tumor activity. Combining dabrafenib
with an AKTi appears to be a promising strategy for
more effective treatment of melanoma patients as
non-MAPK acquired resistance may benefit from the
addition of an AKTi. AKT inhibitors showed synergistic
effect with BRAF inhibitors and are able to reverse resist-
ance to combination of BRAF plus MEK inhibitors. This
is the basis of a phase 1/2 clinical trial (SWOG S1221,
NCT 01902173), which has the goal of determining the
safety of the combination of dabrafenib and the clinical
grade AKTi GSK2141795 in patients with BRAF mutant
cancer. BRAF V600 mutant melanoma patients progres-
sing on prior BRAF inhibitor therapy were enrolled in
this trial. AKT inhibitors (such as GSK2141795B) or
mTOR inhibitor such as rapamycin combined with
vemurafenib or AZD6244 reverses resistance in patient-
derived vemurafenib-primary/-acquired resistant cell
lines [47]. Combination of vemurafenib and rapamycin
analogs such as everolimus and temsirolimus is also
tested in BRAF mutation positive malignant melanoma
(NCT01596140).
Tumor intrinsic pathways such as Heat Shock Proteins
(HSP) can also be targeted. Hsp90s are among the most
abundant proteins in the cell. They make up 1-2% of
total cellular protein, which can increase to 4-6% under
stress. These proteins are essential for proper folding,
maintaining stability and avoiding degradation of a large
number of proteins. Hsp90s consists of a homodimerwith three domains, N-terminal domain with ATP-binding
site, middle domain which bind to client proteins and
C-terminal, responsible for dimerization and binding to
different co-chaperones. XL888 is a novel, water soluble,
orally available inhibitor of HSP90 from Exelixis, Inc. that
is able to induce in vitro apoptosis and cell cycle arrest in
vemurafenib resistant cell lines, leading to degradation of
key proteins implicated in resistance [48].
Other compounds are targeting MDM2. MDM2 can
interfere with p53-mediated apoptosis and tumor growth
arrest. Inhibition of MDM2 can restore p53 activity in
cancers leading to anti-tumor effects with apoptosis and
growth inhibition. Two small molecule inhibitors of
MDM2 JNJ-26854165 [49] and RO5045337 [50] are in
clinical development. p53 mutational status is a predict-
ive biomarkers of MDM2 inhibitor sensitivity because
only melanomas containing wild type p53 were sensitive
to the drug while p53 mutated melanoma did not respond.
Preclinical data demonstrate the synergistic effect of
MDM2i plus BRAFi and combination of BRAFi with
MEKi. Moreover combination of MDM2 and BRAF/
MEK inhibition suppressed growth of human colon
cancer cell line RKO tumor xenograft. These results
have provided an encouraging direction for p53-target
therapeutic strategy utilizing inhibition of MDM2.
Blocking key components of both the tumor and its
micro-environment offers a novel combination therapy
approach for melanoma. Because BRAF targeted therapy
is associated with fast but short-lasting responses the
combination with immune therapy which provides durable
responses has been considered. The first study to combine
immunotherapy and targeted therapy was a combination of
vemurafenib with CTLA-4 check point inhibitor ipilimu-
mab. This study was closed early due to an unexpected
number of hepatotoxic events that were probably related
to autoimmune toxicity [51]. In addition, treatment with
BRAF inhibitors is associated with an enhanced melan-
oma antigen expression, CD8+ T cells infiltration into
tumors and enhanced T cell cytotoxicity. Thus a phase 1
clinical trial of dabrafenib plus ipilimumab in BRAF-
mutated metastatic melanoma patients was initiated in
2013 (NCT01767454). A triple combination arm of dabra-
fenib plus trametinib plus ipilimumab is planned in this
trial. Other trials of sequencing immunotherapy with
combination of targeted therapy have been designed
(vemurafenib/high dose IL-2, NCT01683188).
Another strategy to target tumor microenvironment
is directed towards intratumoral immunosuppressive
myeloid cells, including myeloid derived suppressor cells
(MDSCs) and macrophages is being explored in preclinical
study. PLX3397 is a selective inhibitor of colony stimulating
factor-1 receptor (CSF1R), Kit, and FMS-like tyrosine kin-
ase 3 (Flt3) that down modulates the key cell types involved
in tumor progression including macrophages. Inhibiting
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antitumor activity of tumor-specific T cells. Blocking
myeloid cells recruitment with PLX3397 improved the
efficacy of TCR engineered ACT [52]. Clinical trial test-
ing PLX3397 has been planned for treatment of solid
tumors. The combination of intratumoral macrophage
depletion with PLX3397 also synergizes with BRAFi.
A clinical trial of the combination of PLX3397 and
vemurafenib in BRAF mutated melanoma is currently
open to accrual (NCT01826448).
Targeted melanoma therapy with new drugs, including
selective BRAF-inhibitors, holds great promise; however
this therapy is limited because of the onset of resistance
in most patients within a year. Defective apoptosis path-
ways may be a barrier to effective systemic treatment of
melanoma. The interest in anti-apoptotic proteins has
increased with the development of small-molecule inhib-
itors such as ABT-737, ABT-263 (navitoclax, AbbVie,
Inc.), ABT-199 (AbbVie, Inc.), and GX15-070 (obatoclax,
Cephalon, Inc.).
The group of anti-apoptotic proteins is comprised of
Bcl-2, Bcl-xL, Bcl-w, Bfl-1, and Mcl-1 members pos-
sessing four BH domains (BH1, BH2, BH3 and BH4).
In addition to the BH family, another major group of
proteins called the inhibitors of apoptosis (IAPs) plays
a role in regulating the intrinsic pathway of programmed
cell death. Particularly well-characterized members of this
family include XIAP (X-chromosome-linked IAP), cIAP1
(cellular IAP1), cIAP2 (cellular IAP2), Apollon, ML-IAP
(melanoma IAP), survivin, IAP-like protein 2 (ILP2),
and NAIP (neuronal apoptosis inhibitory protein) [53].
Members of pro-apoptotic proteins group have been
subdivided into two groups: the Bax subgroup that
includes Bax, Bak, and Bok proteins, having three BH
domains (BH1, BH2, and BH3) and the BH3-only group
that includes Bid, Bad, Bik, Bim, Noxa, Puma, and Hrk.
Several apoptosis related proteins have altered expres-
sion in melanoma. Expression of anti-apoptotic mediators
such as Bcl-2, Bcl-xl, Bcl-w, Mcl-1, Bfl-1/A1 and Bcl-B
may affect prognosis and/or response to treatment. For
example, high levels of Bcl-2 can be a marker of good
prognosis considering that Bcl-2 expression is reduced in
progressive lesions. Other studies resulted in inconsistent
results demonstrating that high levels of Bcl-xL and Mcl-1
correlate with tumor progression and they are associated
with poor prognosis. High levels of survivin in sentinel
lymph nodes also indicated poor prognosis as high Bcl-2
and Bcl-xL may confer poor response to chemotherapy.
Other Bcl-2 family members Mcl-1 and Bcl-2A1 are dif-
ferentially expressed in melanoma cell lines and have been
shown to be increased in the melanoma progression.
Strong preclinical data from numerous groups have
shown that targeting apoptosis improves the efficacy
of chemotherapy and molecularly targeted therapy.Subsequently, the Bcl-2 antisense agent oblimersen tested
in a randomized trial comparing the combination of
oblimersen with DTIC vs. single-agent DTIC showed
improved survival in the subgroup of metastatic melanoma
patients with a normal LDH. In phase 2 trial oblimersen
in combination with DTIC obtained a higher objective
response rate of 13.5 vs. 7.5 months, CR 2.8 vs 0.8 and PR
10.6 vs 6.8 months, and resulted in better outcome in
metastatic melanoma patients with normal LDH levels
than in patients with high LDH levels, but these data were
not confirmed in phase 3 trials [54]. A confirmatory phase
3 trial in patients with normal LDH did not show a
survival advantage of the combination, and clinical devel-
opment of oblimersen was discontinued [55]. Mimetics of
the second mitochondria derived activator of caspase
(SMAC) are a new class of targeted drugs being developed
for treatment of solid tumors and hematological cancers.
SMAC mimetic/survivin inhibitor YM155 tested in phase
1 and 2 trials resulted in encouraging safety data, but little
clinical activity in metastatic melanoma [56,57]. ABT-737
mimetic of the BH3 domain of the pro-apoptotic protein
Bad and selectively binds and inhibits the anti-apoptotic
proteins Bcl-2, Bcl-xL, and Bcl-w. The limited efficacy
of ABT-737 as a single-agent therapy indicated that
anti-apoptotic proteins are not effectively targeted by
this drug. Mcl-1 and Bcl-2-related protein A1 (Bfl-1/A1),
play an important role in survival of tumor cells [58]
and small-molecule inhibitors of Mcl-1 may be more
effective against melanoma. Several compounds reported
to be active against Mcl-1 such as obatoclax, prodigiosin,
maritoclax have become available. The principal rationale
for use of BH3-mimetics has been to sensitize cancer cells
to other drugs by reducing their threshold for apoptosis.
BH3-mimetics combination with proteasome inhibitor
bortezomib, alkylating agents, immunotoxins, or cytotoxic
drugs appears promising.
In patients with BRAF mutated melanoma BRAF/
MEK inhibitors have variable effects on Bcl-2 family
protein expression resulting in increased levels of mRNA
for Bim, Bid, Bcl-xL and Bcl-w, while decreased level of
mRNA for Mcl-1 or unchanged level of mRNA for Bcl-
2. BRAF/MEK inhibitors have fewer effects on Bcl-2
family protein expression, and in vitro lead to increased
Bim:Mcl-1 interaction. BH3-mimetics facilitate activation
of intrinsic death pathway and navitoclax and obatoclax
are most complementary to BRAFi [59]. The synergy of
the combination of BRAFi and navitoclax in BRAF mutant
cell lines in vitro has been clearly demonstrated. In vivo,
the combination of BRAFi and navitoclax is associated
with increased magnitude and duration of the response.
Combination of the BRAFi PLX4720 and ABT-737 was
cytotoxic for melanoma cells synergistically in vitro,
depending on the induction level of Bim and down
regulation of Mcl-1 [60]. Importantly, this combination
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from BRAF V600E tumors obtained from patients before
treatment with BRAFi. A more recent study confirmed
the synergy of MAPK inhibitors and BH3-mimetics both
for melanoma and colon cancer cells [61].
ClinicalTrials.gov lists currently 21 trials for navitoclax
and 19 for obatoclax. The most interesting combination
for melanoma patients harboring a BRAF V600E mutation
would be the combination of a BH3-mimetic with a
selective BRAF inhibitor. Indeed, a currently recruiting
trial is studying the side effects and best dose of dabrafe-
nib, trametinib, and navitoclax in patients with melanoma
(NCT01989585/CTEP P9466).
Locoregional interventions can markedly improve
overall survival among melanoma patients whose disease
already disseminated and metastasized. For many years
surgical resection has been the only therapeutic option
to impact on patient’s survival but even in the era of
more effective therapies, locoregional treatment still
remains a vital consideration to improve survival and
reports suggest the curative effect of surgery in certain
patients. Metastastectomy has been associated with favor-
able survival for patients with metastases in the liver, lung,
bowel or spleen/adrenal gland. Appropriate selection of
patients for surgical intervention is critical, and Tumor
Volume Doubling Time (TVDT) and Disease-Free Inter-
val (DFI) are considered prognostic factors. A more rapid
TVDT corresponds generally to a shorter survival [62].
Median overall survival (mOS) of melanoma patients is
about twice longer (30 vs 18 months) if they are stratified
for DFI with a cut off of 36 months; patients with a longer
DFI have longer mOS [63]. Other prognostic factors in
surgically resected stage IV melanoma are the ability to
achieve complete surgical resection of all detectable dis-
ease, number of metastatic lesions (solitary vs. multiple),
initial site of metastasis and the stage. Survival of patients
with more than one lesion is shorter than those with one
metastasis [64] and the site of recurrence has a significant
impact on the outcome of the patient [65]. Multiple single
institution studies indicate longer survival following resec-
tion of multiple distant metastases for melanoma. Longer
survival rates were demonstrated in these studies than in
the data provided by the Korn meta-analysis regarding the
efficacy of multiple cooperative group phase 2 studies in
advanced melanoma [66]. Thus, these data support the
role of surgery in the treatment of advanced melanoma.
Novel targeted therapy and immunotherapy drugs such as
vemurafenib and ipilimumab, respectively, can be inte-
grated with surgical procedures, with an overall impact
on patients’ survival as demonstrated in patients treated
at the National Cancer Institute of Naples using such a
multidisciplinary approach.
Metastasis can be considered a focus of resistance.
Improved survival in metastatic melanoma patients aftersurgery suggests the presence of endogenous anti-tumor
responses [67]. Tumor resection may be associated with
reduced tumor burden and decreased tumor-induced
immunosuppression. Although new effective drugs such
as ipilimumab and vemurafenib can have significant impact
with rapid improvement of symptoms not all metastatic
sites respond to these therapies. Thus, for patients with
mixed or partial responses surgery may be required to
remove resistant lesions. In those who develop solitary
or small number of metastases in the liver, lung, bowel
or spleen/adrenal gland resection can obtain a significant
impact on survival of the patient. Metastases can also be
considered as a vaccine because they are HLA-matched
and represent a “personalized” source of tumor antigens.
Tumor cells elicit an anti-tumor immune response of
which tumor antigen specific T cells are the key regulators.
However, despite the presence of tumor specific T cells
the tumor may continue to proliferate and metastasize.
Tumor resection may augment patient’s endogenous
immune responses and change the balance in favor of
anti-tumor immunity resulting in increased efficacy of
locoregional intervention. In the late 19th Century, William
Bradford Coley, a surgeon of New York, observed that
unresectable sarcomas regressed after superinfection with
erysipelas [68]. Injecting mixed toxins of streptococcus
bacteria causing erysipelas and bacillus prodigious resulted
in regression of disease in more than one hundred and forty
patients. Using the same concept, different experiments
have been performed with the intralesional injection of
interferon, interleukin 2, GD2 ganglioside specific MAb,
oncolytic herpes virus encoding GM-CSF or BCG that
obtained about 80% of responses [69].
Electrochemotherapy (ECT) combined with other treat-
ments can also provide improved modality therapy for
melanoma patients. This technique combines chemother-
apy (bleomicin or cisplatin) with electroporation induced
by needles inserted into the metastatic lesions that give
an electric impulse (electroporator). Electroporation
performed with some intratumoral short and very high
voltage electric impulses facilitate the opening of trans-
membrane channels that allow delivery of non-permeant
drug to the cell interior. As a result of transient permea-
bilization of the cell membrane even high molecular
weight chemotherapy agents (bleomicin), which normally
can’t get inside can diffuse inside the cell. With this pro-
cedure bleomicin concentration inside the cell increases
about 10000 times than in standard therapy resulting in
apoptosis of cancer cells. Indications of ECT application
are the following: in-transit disease not amenable to sur-
gery (multiple lesions that are not > 3 cm); early cutaneous
relapses after previous surgical treatment; complete or
partial responses after previous ECT treatment; palliative
purpose (i.e., hemostatic or painful lesions) or as a neoad-
juvant (extensive lesions or to reduce surgical approach).
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tute of Naples (160 patients treated with ECT for 224
treatments) shows that different types of cancer can be
treated with ECT including melanoma, squamous cell
carcinoma, basal cell carcinoma, breast cancer and others.
ECT can also be combined with the new anti-melanoma
drugs, ipilimumab and/or vemurafenib. Another form of
locoregional treatment for metastasis in case of liver
metastases is liver perfusion as palliative treatment [70].
Although systemic treatment approaches for melanoma
continue to evolve including emerging therapies (targeted
and immunotherapies) local therapies including surgery
or liver perfusion play an important role in the multidis-
ciplinary management of melanoma. Thus in the future,
advanced melanoma patients might benefit the most
from a multimodality treatment including chemotherapy,
targeted therapy, immunotherapy, radiotherapy, surgery
and ECT options.
Problems in combining targeted drugs are dosing,
targeting and tumor evolution. Combination targeted
therapies are designed to overcome drug resistance.
After all, combination therapy is effective for infectious
diseases e.g., HIV, bacterial infections and tuberculosis.
Combination cytotoxics also work well for haemato-
logical malignancies/germ cell tumours even if they are
less efficacious for advanced solid tumours and are not
curative. Often oncologists have combined drugs simply
because they can but combining drugs at full single
agent dose almost always increases side effects. This is
acceptable if cure rate is increased or survival prolonged,
but in melanoma historically combination cytotoxic
chemotherapy/immunotherapy increased toxicity with-
out survival benefit. The combination of BRAFi plus
MEKi however has shown impressive results in clinical
trials. For example, vemurafenib and cobimetinib in the
BRIM 7 trial gave an 85% objective response rate and
98% control disease rate [10]. Dabrafenib and trameti-
nib showed a higher efficacy compared with dabrafenib
with a lower toxicity related to paradoxical MAPK
pathway activation, as discussed earlier [9]. So the com-
bination of BRAFi plus MEKi is possible at the full dose
and with a better safety profile.
Most targeted drugs have a dose–response relationship
for efficacy and toxicity and a narrow therapeutic index
and approved doses are often close to maximum toler-
ated dose (MTD); dose reduction therefore may lead to
reduced efficacy. Combination very often leads to dose
reduction because of toxicity. In some cancers such as
RCC this is well illustrated and the same is true for ex-
ample in combining MEKi with PI3K or AKT inhibitors:
full dosing is not possible. Dose reduction might not be
a problem if you know that tumour A in patient B at
time point C in metastasis D only needs 25% inhibition
of pathway E (e.g. PI3K) and 50% inhibition of pathwayF (e.g. MAPK). This is not easy information to gather
currently. Relatively non-invasive tests are obviously
needed to acquire this information and even ‘liquid biop-
sies’ still need to be validated with a gold standard.
Under the selective pressure of therapy tumours evolve
to be resistant to treatment. So intratumoral heterogeneity
is another problem to combine anti-cancer drugs; in
advanced RCC, 65% mutations may be heterogeneous and
not present in every biopsy [71]. Intratumoral heterogen-
eity/branched evolution can be considered a substrate for
Darwinian selection and this has been demonstrated in
multiple solid tumour types, including melanoma [72].
Targeted therapies are a fixed selective pressure so out-
growth of drug resistant subclones is largely inevitable.
Combining targeted (or cytotoxic) drugs simply provides a
different, but still fixed, selective pressure. Immuno-
therapy works differently. Speculating on this, successful
immunotherapies may not be a fixed selective pressure,
rather a “reprogramming” of the immune system i.e. “a
dynamic solution to a dynamic problem”. Intermittent
targeted therapy may mitigate the problem of a fixed
selective pressure. In mice intermittent therapy gives an
alternating selective pressure that prevents emergence
of a resistant population [44].
To summarize, combining targeted drugs rationally may
delay but will not prevent drug resistance in advanced solid
tumours. The challenges for rationally combining targeted
drugs are significant: dosing, targeting and tumour evolu-
tion. Immunotherapies may circumvent tumour evolution,
perhaps because they do not provide a fixed selective
pressure. There will always be a need for targeted drugs
(and cytotoxics). However, the development and use of
better drugs must be informed by greater understanding
of disease biology.
News in immunotherapy
New therapies for metastatic melanoma, such as cyto-
toxic T-lymphocyte associated antigen-4 (CTLA-4) and
programmed cell death protein 1 (PD-1)/programmed
cell death ligand 1 (PD-L1) pathway blocking antibodies
have yielded promising results, changing the continuously
evolving landscape of therapeutic options for patients with
this disease. Unlike the CTLA-4 antibody blockade, which
is thought to act in secondary lymphoid structures, the
PD-1/PD-L1 antibodies aim to potentiate the antitumor
T cell response at the tumor site, by impairing the
interaction of the inhibitory receptor PD-1 on T cells
with PD-L1 expressed on tumor cells. Other monoclonal
antibodies under investigation in the immunotherapy of
melanoma include those targeting the receptors CD40,
CD137 (4-1BB), OX40, glucocorticoid-induced tumor
necrosis factor receptor (GITR), KIRs, LAG-3 and trans-
forming growth factor beta (TGFβ). Understanding the
mechanism of action of these therapies can provide new
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that can result in selection of patients with a high likeli-
hood of response. The use of new immunologic agents in
monotherapy and in combinations including targeted
therapies will dramatically change the current manage-
ment of patients with melanoma. Considering all these
options the future of therapy including adjuvant therapy
in melanoma appears very promising.
Goals for adjuvant therapy have historically been the
improvement of Overall Survival (OS), and Relapse-free
Survival (RFS). The improvement in RFS alone is enter-
tained only if improved OS is not attainable. Consistency
of adjuvant treatment impact across risk groups (IIB/
IIIA & IIIB-IV) differs as this has been analyzed for
previous adjuvant therapy trials. A goal of our efforts
has been to identify the right patient for therapy, to
optimize anti-tumor effects or to reduce the toxicity of
the treatment. Understanding mechanism(s) of action of
the therapy can take to new rational combinations and
identify biomarkers of benefit can give more selectivity
to improve therapeutic index. Two options for adjuvant
therapy exist in the US for postoperative management of
patients with high-risk melanoma. Agents active in adju-
vant therapy are high-dose (HD) IFNα (HDI), approved
by the US FDA in 1996, and pegylated (Peg)-IFNα
approved in 2011. Adjuvant trials of ipilimumab adminis-
tered at 10 mg/kg compared to placebo (EORTC 18071)
and of ipilimumab at 10 mg/kg or 3 mg/kg compared to
high-dose IFNα (ECOG led US Intergroup E1609) are
pending the outcomes of current trials. For the future,
trials testing anti-PD-1, anti-PD-L1 and BRAFi, as well as
BRAF plus MEKi combination as well as vaccines are
being evaluated.
From 1996 there have been more than 20 trials reported
evaluating various formulations, dosages, routes of dosing
and durations of therapy to determine the “right” regimen
of adjuvant therapy and to evaluate the “right” setting of
disease for adjuvant therapy. The Cochrane Analysis of all
reported adjuvant trials from 1995 to 2011 (17 Trials;
10,499 patients) showed a Hazard Ratio (HR) for RFS of
0.83 (0.78-0.87) among 10,345 pts (17 studies), an HR
of 0.91 (0.85-0.97) for OS on 9927 subjects (15 studies),
relapse risk reduction from 50/100 to 44/100 with a
number needed to treat (NNT) for benefit in one of 16
and a reduced mortality risk from 40/100 to 37/100 with
commensurate NNT of 33. The Cochrane Analysis of IFN
impact on RFS across studies, showed no significant
heterogeneity for individual factors that significantly
affect IFN impact on RFS (Subgroup analysis and
meta-regression), for dosage tested, TNM stage, year
of publication and treatment duration.
A fundamental assumption of adjuvant therapy is that
treatment efficacy in advanced disease predicts adjuvant
impact, and that the benefit in the earlier disease settingmay exceed that in the setting of advanced inoperable
disease. An impact upon OS may be anticipated if the
benefit upon PFS HR is ~0.70 in IIIA&B. Combinations
of drugs ought to build on therapeutic mechanism of
action. Biomarkers will focus applications to improve
risk-benefit ratio. Earlier disease will show improved gains
in mortality, recurrence-free survival, and morbidity
E1684, E1690, and E1694 trials showed durable and
significant impact of adjuvant IFN upon RFS and OS,
but mature outcomes for RFS, distant metastasis-free
survival (DMFS), and OS in EORTC 18991 Trial of Peg-
IFNα × 5 years for stage III melanoma did not confirm
the advantage of adjuvant therapy with no impact upon
OS or DMFS.
Some points are still unresolved, such as the optimal
duration of treatment and the optimal dosage of IFN. It
is clear that the only trials that have shown independent
statistically significant improvement in both RFS and OS
are the E1684 and E1694 trials, however. In regard to
the optimal duration of therapy, it is also clear that one
month of high-dose IFN is ineffective in improving OS,
as this was tested in the US Intergroup ECOG-led E1697
trial. This large intergroup trial tested 1 month IFNα-2b
vs. observation, and demonstrated that 1 month of HD-
IFN is futile in IIA-IIIA patients. The Hellenic 13A/98
and Oxford Trials compared 1 month of attenuated IFN
for 1 year in IIIAB with 1 month attenuated dosage
HDI. The former showed no significant difference while
the latter trial has recently shown improvement in the
OS of patients with one year as opposed to 1 month of
full HDI. The EORTC 18991 trial tested up to 5 yrs. of
Peg-IFNα-2b in IIIAB and showed a relapse reduction
that was marginal as currently updated [73] with a benefit
in N1 but not N2 (IIIB). In this trial RFS benefit at
3.8 years resulted 18%, significant response, but at 7.6 years
becomes marginal 13%, and there was no significant
impact on DMFS or OS at maturity or 3.8 years. Stage III
N1 disease showed significant RFS and DMFS in 2007,
but improvements at 7.6 years are no longer statistically
significant while patients with stage III N2 show no
significant benefit at any endpoint. Mature outcomes for
EORTC 18991 confirm that N1 from ulcerated melanoma
is the subset showing greatest benefit with median OS
Peg-IFN vs. observation with > 9 vs. 3.7 years. For this rea-
son the EORTC 18081 trial that will compare Peg-IFN ×
2 yrs. vs. observation in ulcerated primary tumors was
designed. The optimal dosage of adjuvant HD-IFN has been
evaluated in relation to RFS HR of 0.61-0.72 in pivotal and
sequel trials consistent w/ OS HR 0.67-0.75. Benefit across
stages IIB-IIIA-IIIB (RFS/OS) was restricted to IIIA (RFS)
for Peg-IFN. Duration of actual therapy with HDI and
Peg-IFN remain similar even if a dose response relation-
ship remains unclear. Peg-IFNα is an alternative approved
option in U.S., but more data are needed from 18081 trial.
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limumab has been tested in the adjuvant setting with the
EORTC 18071 trial (ipilimumab 10 mg/kg vs. placebo)
where RFS is the primary endpoint. Data is due in mid-
2014 and the US Intergroup E1609 (ipilimumab 10 mg/kg
or 3 mg/kg vs. HD-IFN (HDI) evaluates this treatment
effect in relation to co-primary endpoints of OS & RFS.
Closure of this trial is anticipated to also occur in mid-
2014. This phase 3 trial of ipilimumab vs. HDI has been
designed to verify the advantage of ipilimumab at the
higher dosage of 10 mg/kg, and also to evaluate the lower
US FDA approved dosage of 3 mg/kg of anti-CTLA-4 Ab
as adjuvant therapy vs. HD-IFN.
New options of adjuvant therapy include a range of
drug combinations with HD-IFNα. The combination
of ipilimumab and HD-IFNα was demonstrated to be
active and potentially additive in phase 2 trial setting
for metastatic melanoma. An objective response rate
of 26% with 21 months median OS and 6.4 months
median PFS was obtained [74]. A phase 2 trial of ipili-
mumab at two different doses (3 or 10 mg/kg) combined
in a 2x2 factorial design with HD-IFNα is in progress
(ECOG-ACRIN trial E3611). Neoadjuvant evaluations of
IFN at high dosage, ipilimumab at high dosage (10 mg/kg,
UPCI 08–144) have been completed and published [75].
Currently, a neoadjuvant trial evaluating the combination
of ipilimumab and IFNα is in progress (UPCI 11–063)
and a trial of anti-PD-1 and IFN is designed and awaiting
activation. In BRAF mutated melanoma patients the
combinations of BRAFi and IFNα are under investigation
through the University of Pittsburgh SPORE Program
in Melanoma and Skin Cancer designed to treat BRAF-
mutated patients with BRAFi followed by IFN (UPCI
12–107 trial).
Data from the UPCI 08–144 trial, neoadjuvant ipilimu-
mab in N1b, 2b, N2c, N3 melanoma patients, evidenced
an increase in tumor TILs during treatment. IL-17 levels
at baseline (p = 0.02), and week 6 (p = 0.06), and change
(p = 0.05) were documented to correlate with GI toxicity
and the occurrence of grade 3 diarrhea. Flow cytometry
analysis (N = 27) shows a rise in circulating Tregs and
drop in MDSC that are associated with improved PFS
(p = 0.034; HR = 0.57).
Other trials have addressed the potential role of other
adjuvant therapies for high-risk resected melanoma, includ-
ing chemobiotherapy. This was tested in the phase 3 S0008
trial of HD-IFNα-2b vs. cisplatin, vinblastine, DTIC, IL-2
and IFN in high risk melanoma. This showed significant
differences in RFS over HDI unfortunately without any
differences in OS [76].
Second generation of immune checkpoint Inhibitors,
namely anti-PD-1 and anti-PD-L1, have shown single agent
response rates that are unprecedented and the durability of
impact favors adjuvant role even considering the favorabletoxicity profile. For all these reasons there is an important
potential for combination of IFN and vaccines. IFN
induction of PD-L1 may sensitize for greater anti-PD-1
effects but the data regarding PD-L1 expression in RLN
and in IIIA, IIIB melanoma is not available. The Inter-
group S1404 Adjuvant Trial to follow intergroup E1609,
has been designed to compare anti-PD-1 MK3475 MAb
at 10 mg/kg every 2 weeks for 6 months followed by
10 mg/kg every 3 weeks for 2 doses, with HD-IFNα-2b, 20
MU/m2/day IV d. 1–5 × 4 weeks, and 10 MU/m2/day SC
q.o.d., three times weekly to 48 weeks. Co-primary end
points of this trial are RFS and OS; secondary end points
are toxicity and immune correlatives (PD-L1 expression,
tumor infiltrating lymphocytes, autoimmunity etc.). Con-
sidering all these options the future of adjuvant therapy in
melanoma is more promising now than ever before in his-
tory. The use of new immunologic and targeted agents in
monotherapy and in combinations, with the understand-
ing of mechanism(s) of therapy and with the definition of
prognostic and predictive biomarkers will dramatically
change the adjuvant therapy.
There are two types of interferons (IFN), type I including
IFN (α, β, ε, κ, ω) and type II (IFN γ). IFNα was FDA
approved for application as adjuvant therapy for melanoma
as discussed earlier. Type I IFNs perform their function by
interaction with a specific transmembrane interferon alpha
receptor, IFNAR I, which activates an intracellular pathway
via STAT1 and 2 signaling. IFNAR1 expression is affected
by activated ERK that induces the ubiquitination and deg-
radation of IFNAR1 by β transducing repeat-containing
protein 2 (βTrCP2) that is a subunit of E3 ubiquitin ligase
complex. As a result, negative correlation of p-ERK with
IFNAR I levels is observed in melanoma cells as IFNAR1
expression is down regulated by activated ERK. Conversely,
IFNAR1 expression is up-regulated in BRAFV600E mu-
tated melanoma cells treated with BRAF inhibitor, as
demonstrated in pre-clinical models (Ferrone S, unpub-
lished data). BRAF inhibition up-regulates IFNAR1
expression and enhances the functional properties of
IFNα-2b by increasing its anti-proliferative activity and
pro-apoptotic activity. Treatment of melanoma cells with
BRAFi in vitro enhances the induction of HLA Class I
antigen processing machinery (APM) components and
melanoma cell sensitivity to recognition by cognate T
cells. Thus the in vivo data confirm the in vitro results
demonstrating the ability of the combination of BRAFi
and IFNα-2b to exert anti-tumor activity and to prolong
the survival of immunodeficient mice grafted with human
BRAF mutated melanoma cells.
Although IFNα-2b is used as a standard treatment in
melanoma side-effects may hamper reaching and main-
taining the dose needed for maximal therapeutic effect
and their occurrence can outweigh clinical benefit of
IFNα treatment. To overcome this limitation in a clinical
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to melanoma cells utilizing chondroitin sulfate proteo-
glycan 4 (CSPG4)-specific MAb as a carrier is being
explored. CSPG4 is a membrane bound high molecular
weight-melanoma-associated antigen (HMW-MAA) which
is highly conserved through phylogenetic evolution. CSPG4
is expressed with high density on the membrane of
malignant cells in various types of tumors including
melanoma (~85%), glioma (~70%), head and neck squa-
mous cell carcinoma (~60%), basal breast carcinoma
(~80%), mesothelioma (~50%), chordoma, chondrosarcoma
and osteosarcoma (~50%) and 11q23 positive acute
leukemic (~20%) specimens. CSPG4 is expressed on
cancer stem cells and on tumor activated pericytes, and
has a restricted distribution in normal tissues. Because
of its high expression on melanoma cells CSPG4 can be
a useful delivery target for toxin conjugates or cytokines.
Combination of IFNα delivery via IFNα-conjugated to
CSPG4-specific MAb and up-regulation of HLA Class I
antigen expression on M21 BRAF-mutated melanoma cell
line treated with BRAFi suggests the feasibility of this
approach for clinical application [77].
Concluding, ERK activation level correlates with IFNAR1
expression in melanoma and IFNAR1 level correlates with
HLA class I expression. CSPG4-specific monoclonal anti-
bodies can be useful carriers to deliver IFNα-2b to melan-
oma cells. BRAF inhibition enhances IFNAR1 expression in
melanoma cells with a constitutively active mutated BRAF
and enhances the functional activity of IFNα-2b suggesting
that metastatic BRAF-mutated melanoma patients could
benefit from the combination of IFN and BRAF inhibitor
treatment.
Immune escape strategies of melanoma involve tumor
cells, the tumor micro milieu and tumor infiltrating
immune cells. Mechanisms linked to tumor cells can be
the deficient expression and function of the MHC class
I complex and components of the antigen processing
machinery (APM), IFN signaling or other signaling path-
way alterations. HLA class I abnormalities can be due
to the total HLA class I antigen loss, HLA class I
down-regulation, selective loss or down-regulation of
HLA class I allospecificities and decreased level or loss
of a single or multiple APM components [78]. These
alterations are more frequently observed in metastases
when compared to primary tumor lesions, are associated
with disease progression, and also correlate with tumor
staging/grading, poor prognosis and reduced patient
survival. In addition, HLA class I APM deficiencies could
be induced during immunotherapy including adoptive
T cell transfer leading to the development of immune
escape variants. Different molecular mechanisms such as
structural alterations of APM genes (mutations, deletions
or LOH), epigenetic control, transcriptional or post tras-
criptional modifications can be responsible for HLA classI defects. While structural alterations and epigenetic silen-
cing are rare events transcriptional down-regulation is
often responsible for impaired APM expression. In
addition, post-transcriptional modifications, which are
less frequent than the transcriptional control, could also
regulate APM molecule expression. For example, down-
regulation of mRNA and protein expression or proteasomal
degradation of (Transporter associated with Antigen
Processing) TAP1 in tumor cells leads to reduced sur-
face expression of MHC class I antigens. Impaired
TAP1 expression could also be directly associated with
deficient TAP2 expression since TAP1 exerts a stabilizing
function for the TAP1/TAP2 heterodimer.
A role of microRNAs (miRs) is suggested in the dis-
cordant expression of transcriptional control of APM
components. Strategies used for identification of HLA/
APM-specific miRs include miR array analysis of cell
lines/tissues with aberrant and discordant HLA/TAP1
mRNA and protein expression, in silico prediction of
candidate miRs, binding of miRs to 3‘-UTRs (miTRAP,
enrichment of miRs, luciferase promoter analysis) and
functional assays. The results lead to the identification
of a number of APM-specific miRs including miR-200a*.
An inverse correlation of TAP1 and miR-200a* expression
was observed in human embryonic kidney HEK293T
cells and melanoma cells. Overexpression of miR-200*
corresponds to a reduced expression of TAP1 that
correlates with reduced HLA class I surface expression
which in turn enhanced NK cell recognition via targeting
MEKK2-MEK5-ERK5 pathway (Seliger B., unpublished
data). These data suggests that lower levels of HLA class I
antigens in melanoma cells might be the consequence of
down-regulation of TAP1 protein expression via TAP1-
specific miRs [78].
Immune escape can be also mediated by altered signal-
ing pathways in melanoma. Strong evidence suggests a
link between IFN signaling and HLA class I APM compo-
nents expression. Different mechanisms of IFN resistance
such as defects in members of IFN signaling pathway have
been identified [79]. In addition, modulation of basal HLA
class I APM components expression by impaired IFN
signaling has been implicated. Possible defects of the type
I and II IFN signaling pathways involve IFN receptors,
JAK/STAT signaling components, interferon regulatory
factors (IRFs) or IFN-responsive elements. Lack of JAK2
expression seems to correlate with impaired IFNγ activity
on tumor cells. Correlation of JAK2 function with
IFNγ response of melanoma cells was demonstrated
by restoration of IFN function by JAK2 overexpression
in JAK2-deficient melanoma cells. Furthermore, HLA
class I APM components expression was enhanced by
JAK2 transfection in JAK2-negative cells. The JAK2
inhibitor-mediated down-regulation of APM and HLA
class I surface expression and suppression of HLA
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shRNA was also shown. These data demonstrate a
close correlation between HLA class I APM expression
and JAK signaling. Interestingly, similar results were also
found by modulation of STAT1 [80].
HLA class I antigens are also influenced by tumor sup-
pressor and oncogene (e.g., BRAF) and signal transduction
activity that could cause a reduced sensitivity to T cell-
mediated cytotoxicity [81]. The BRAFi vemurafenib is able
to restore HLA class I APM expression and immune
response suggesting a link between immune evasion
and immune recognition in BRAF-mutated melanoma.
B-RAF and N-RAS signaling have effect on HLA class I
APM and immune response in melanoma due to altered
expression of transcription factors. The transcription
factor E2F1 regulates the expression of tapasin, another
protein playing a role in the peptide-loading complex of
MHC class I [82]. In addition, activation of the cAMP
response element binding protein (CREB) by phosphoryl-
ation, which is frequently overexpressed in melanoma
cells, demonstrated a CREB-mediated regulation of genes
involved in different cellular processes. Thus, the under-
lying mechanisms of HLA class I abnormalities are diverse
and a better understanding of this complexity might help
to revert these deficiencies.
Immune checkpoint receptors are inhibitory molecules
(CTLA-4, PD-1, Tim-3, and Lag-3) that are up-regulated
on activated T cells to terminate effector T cell responses
and restore immune homeostasis. Sustained expression
of these molecules on T cells leads to T cell dysfunction/
exhaustion, while their expression on T regulatory cells
(Tregs) promotes suppressor function. Blocking inter-
action between the inhibitory check point receptors and
their ligands become an attractive strategy for cancer
immunotherapy. Tim-3 is a member of T cell immuno-
globulin and mucin domain 3 (Tim-3) family of proteins
which are selectively up-regulated on CD4+ and CD8+ T
cells activated to differentiate to IFNγ-secreting pheno-
type. Tim-3 has been shown to interact with a natural
ligand Galectin-9 that is up-regulated by IFNγ and
expressed on many tumors. Tim-3 mediated response
also depends on phosphatidylserine (PtdSer) and High-
Mobility Group Box 1(HMGB1) protein that is actively
secreted after cell stress and plays a role in inflammation
and immune responses. In cytoplasmic tail Tim-3 has 6
tyrosine residues that can be phosphorylated and can
interact with proteins involved in signal transduction.
High frequency of T cells co-expressing CD8+Tim-3+
PD-1+ among tumor infiltrating lymphocytes has been
identified and Tim-3 is a marker of the most exhausted
CD8+ TILs. In syngeneic transplantable tumor models,
anti-Tim-3 antibody synergizes with anti-PD-L1 anti-
body to suppress tumor growth. In vitro studies showed
that blockade of both the Tim-3 and PD-1 pathwaysrestores effector function of CD8+ T cells. Tim-3 blockade
increases frequency of proliferating tumor-reactive T cells
and frequency of cytokine producing tumor-reactive T
cells [83]. Tim-3 is highly expressed on the transcription
factor forkhead box p3 (FoxP3+) positive Tregs. Tim-3+
Tregs are present in tumor tissue and Tim-3+ Foxp3+
Tregs are potent suppressors of the local immune
response. Tim-3+ Tregs secrete perforin and granzymes
A and B as cytotoxic effector molecules to kill or deliver a
negative signal to responder T cells. Tim-3/PD-L1 block-
ade in vivo down-modulates genes associated with Tregs
suppressor function. Presence of Tim-3+ Tregs precedes
the appearance of Tim-3+ exhausted CD8 TILs implying
that Tim-3+ Tregs may drive T cell exhaustion process. In
absence of Foxp3+ Tregs alterations in phenotype of CD8
TILs and the emergence of Tim-3+ PD-1− CD8 TILs have
been observed [84].
Since CD4+ and CD8+ T cell populations emerging post
Tregs depletion exhibit properties of effector T cells and
express Tim-3, they could be subject to Tim-3-mediated
negative regulation. Indeed, Tregs depletion with a single
administration of diphtheria toxin (DT) delayed colon car-
cinoma CT26 cells tumor growth transiently in syngeneic
transplantable tumor model and administration of anti-
Tim-3 antibody to Tregs depleted mice resulted in sig-
nificant and sustained tumor regression. The synergistic
effect of Tregs depletion and Tim-3 blockade has been
repeatedly seen in MC38 colon adenocarcinoma and
B16 melanoma mouse models. These data demonstrate
that Tim-3 blockade after Tregs depletion relieves the
Tim-3-expressing CD4+ and CD8+ T cells from Tim-3-
mediated negative regulation, resulting in enhanced anti-
tumor effector responses and control of tumor growth.
These findings provide proof-of-principle for the combin-
ation of Tim-3 blockade with Tregs-targeted therapies
for cancer treatment. IL-27 is a potent inducer of Tim-3
and in the absence of IL-27 signaling in vivo there is a
defective Tim-3 expression and delayed tumor growth,
potentially due to improved effector T cell function.
Several issues should be addressed for clinical develop-
ment of Tim-3 targeted therapy. A confounding issue is
the selection of an isotype of a candidate anti-Tim-3
antibody (IgG4 or IgG1). Another factor is the ability to
block specific ligand interaction among a number of
Tim-3 ligands that have been proposed (Galectin-9,
PtdSer or HMGB1). Although the use of anti-Tim-3 MAb
as a single agent seems promising, the determination
which agents will work best with Tim-3 blocking MAb
(e.g., anti-PD-1/PD-L1 or Lag-3) will drive development
of combination therapy.
The tumor microenvironment offers multiple targets for
immune system manipulation. Combined interventions
targeting different mechanisms within the microenviron-
ment are feasible and might result in more effective
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antibodies can function as agonists of immune-stimulating
receptors (CD137, CD40, OX40, GITR, CD27) or as antag-
onists of immune inhibitory receptors (CTLA-4, PD-1,
B7-H1, BTLA, TGF-β, IL-10), and early data have sug-
gested clinical utility. CD137 (also known as 4-1BB) is a
member of the tumor necrosis factor (TNF) receptor
superfamily, and it is an activation-induced T cell co-
stimulator molecule. CD137 is a surface glycoprotein
and it is mainly expressed on activated CD4+ and CD8+
T cells, activated B cells, and natural killer (NK) cells but
can also be found on resting monocytes and dendritic
cells (DCs). Its cognate ligand CD137L is expressed on
APCs including B cells, monocyte/macrophages and
DCs. As a co-stimulatory molecule, CD137 is involved
in the activation and survival of CD4+, CD8+, and NK
cells. CD137 is also involved in T cell proliferation,
inhibition of apoptosis, enhances cytotoxic activity, and
influences cytokine production.
Development of CD137-specific MAb began in 1997,
and anti-human CD137 agonist MAbs are undergoing
testing in phase 1 and 2 clinical trials. Treatment with
anti-CD137 MAb can overcome tumor antigen tolerance
as it affects memory CD8+ T cell resulting in antigen-
independent activation. Treatment of activated CTLs
with anti-human CD137 agonist results in resistance to
apoptosis, improved proliferation, augmented effector
function, and improved differentiation to memory cells.
Treatment of activated NK cells with anti-human CD137
agonist MAb activates early cytokine production and early
tumor cell cytotoxicity. Overall, stimulation of TILs and
NK cells with anti-CD137 increased their cytolytic activity
for tumor cells. NK cells upon Fc-receptor triggering, for
example by antibody-bound tumor cells (e.g., trastuzu-
mab), up-regulate the inducible co-stimulatory molecule
CD137. Thus the cytotoxic function of activated NK
cells can be enhanced by their exposure to an agonistic
MAb against CD137 which can synergize with treatment
with rituximab, trastuzumab and cetuximab to improve
anti-tumor response.
Tumors are known to be hypoxic and the expression
of CD137 has been demonstrated in tumors at 1% O2
conditions suggesting that expression on endothelial cells
could be driven by hypoxia [85]. Moreover, treatment
with anti-CD137 MAb resulted in enhanced expression
levels of ICAM-1 and VCAM-1 on tumor endothelial
cells. Considering, that hipoxia inducible factor (HIF)α
is produced in response to hypoxic conditions, the HIF1α
pathway becomes activated in tumors. Consequently,
HIF1α is able to induce CD137 expression on antigen-
primed TILs.
Systemic effects of the anti-CD137 MAb have also been
demonstrated in mouse models. The CD137 protein itself
lacks any known intrinsic enzymatic activity and has beenshown to use TNF-receptor-associated-factor (TRAF)-1,
TRAF-2 and TRAF-3 as downstream molecules to
translate signals towards the cell interior [86]. TRAF2
has been shown to function as an E3 ubiquitin ligase that
ubiquitinates itself and other substrates. The Lysine (K)
63-Polyubiquitynation of TRAF-2 is likely to be a key
step in the understanding of the physiology of CD137.
In vitro and in vivo experiments documented that the
CD137-dependent K63-polyubiquitination activates the
transcription factors such as nuclear factor (NF)-kB and
activator protein 1 (AP-1) and thereby modifies expression
of many genes at a transcriptional level. The signals
through CD137 ligand are also mediated by protein tyro-
sine kinase p38 MAPK. T cell homing into tumor lesions
inducible with treatment with anti-CD137 agonist MAb
was demonstrated in mouse model. Inhibition studies
using anti-ICAM-1 and anti-VCAM-1 antibodies showed
that the stimulation of ICAM-1 and VCAM-1 expression
on tumor endothelial cells by anti-CD137 Ab was respon-
sible for the enhanced T cell migration into tumor tissue.
Anti-human CD137 MAb tested in mouse model as
monotherapy resulted in systemic effects. In addition,
anti-CD137 MAb effect was synergistic with other
immunostimulatory monoclonal antibodies, adoptive T
cell therapy, and conventional chemo- and radiotherapy.
Triple combination treatment obtained important tumor
regression and a significant impact on overall survival
[87]. Significant impact of the triple therapy was evidenced
in CD8 TILs count. Growing evidence indicates that anti-
CD137 monoclonal antibodies possess strong anti-tumor
properties due to their powerful capability to activate
CD8+ T cells, to produce interferon IFNγ, and to induce
cytolytic effector molecules. Currently, anti-CD137 MAb
(BMS-663513) is being evaluated in several clinical trials
in patients with solid tumors, including melanoma, renal
carcinoma, ovarian cancer, and B-cell malignancies.
Adoptive Cell Therapy (ACT) using Tumor Infiltrating
Lymphocytes (TILs) has become more successful with an
observed clinical response rate from 10 to 70% in patients
with metastatic melanoma and its use is spreading.
TILs are re-infused after isolation from fresh tumor
specimens, enrichment and expansion with IL-2 plus
anti-CD3 antibody in the presence of feeder cells. Pre-
treatment leukocyte depletion enhances TILs therapy
clinical outcomes. Radiotherapy and chemotherapy have
been used for leukocyte depletion and can be either
non-myeloablative or myeloablative. TILs and non-
myeloablative lymphocyte depleting chemotherapy for
metastatic melanoma have resulted in significant clin-
ical responses [88]. In a recent clinical trial of TIL
therapy among 57 patients treated, 5 CRs and 18 PRs
were obtained; medianOS of non-responder patients
was 6.1 months, while medianOS of all the patients
was 15.2 months [89]. The median OS of responder
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more than 50 months. Interestingly, shorter duration of
expansion, greater expansion and infusion of more CD8+
cells is associated with better clinical outcomes.
Improved molecular biology techniques have increased
the feasibility for the clinical application of genetically
engineered T cells which have been designed to express
tumor antigen specificity. Two types of engineered T cells
have been developed to overcome poor antigenicity of the
tumor and to generate T cells with high avidity for tumor-
specific antigens, i.e., high-affinity TCRs and Chimeric
Antigen Receptors (CAR). In the first approach T cells are
being transduced to express natural αβTCR heterodimers
of known specificity and avidity for tumor antigens. Pre-
liminary results of ACT with genetically engineered T cells
have been promising. Treatment with genetically engi-
neered lymphocytes expressing NY-ESO-1 antigen specific
TCRs resulted in clinical responses in 5 of 11 melanoma
and in 4 of 6 synovial sarcoma patients [90]. Genetically
engineered lymphocytes reactive with MAGE-A3 obtained
clinical responses in 5 of 9 treated patients [91].
CAR therapy involves the generation of T cells with
chimeric receptors that have antibody-based external
receptor structures and cytosolic domains that encode
signal transduction modules of the T cell receptor. These
constructs can function to retarget T cells in vitro in an
MHC-unrestricted manner to attack the tumor while
retaining MHC-restricted specificity for the endogenous
TCR. Clinical results of CAR T cell therapy have been
encouraging. Among 8 patients with B-lineage hematologic
malignances treated at the NCI with autologous anti-CD19
CAR T cells, 6 clinical responses were achieved [92].
Other CAR T cells being tested in clinical trials are anti-
CD20 in B cell lymphoma, anti-GD2 in neuroblastoma
and osteosarcoma, and anti-ERBB2 (HER-2/neu) in colon
cancer. CAR T cells in development include anti-CD22,
anti-CD23, anti-CD70, anti-Immunoglobulin Kappa light
chain, anti-B cell maturation antigen (BCMA) for multiple
myeloma, anti-Glypican 3 for hepatocellular carcinoma,
and anti-Erythopoietin-producing hepatocellular carcin-
oma A (EphA2) for glioblastoma.
It may also be possible to improve adoptive cellular
therapy by making use of T cells with less differentiated
phenotype. The population of memory T cells with en-
hanced stem cell-like (TSCM) qualities compared to known
memory populations displays enhanced self-renewal and
multipotent capacity to derive central memory effector
memory and effector T cells. In mouse models adoptively
transferred Mesothelin-specific TSCM cells demonstrated
increased proliferative capacity, more efficiently reconsti-
tuted immunodeficient hosts and mediated superior anti-
tumor responses in a humanized mouse model [93].
Since genetically engineered T cells are clinically effect-
ive and are relatively easy to manufacture and some of thetechnologies related to T cell engineering are protected by
intellectual property, companies have become interested in
developing commercial T cell therapies. As a result of this
increased interest on ACT manufacturing methods for
generating cellular anti-cancer therapies are improving.
Ipilimumab, the anti-CTLA-4 MAb, induces tumor
necrosis, infiltrates of lymphocytes and vasculopathy.
Angiogenesis has an important role in immune suppres-
sion, and in a study of melanoma patients treated with
ipilimumab changes in distribution of VEGF at baseline
and week 12 were observed. Changes of VEGF levels
were observed in some melanoma patients relative to
treatment, but these were not correlated with clinical
outcomes. Baseline VEGF value correlated with overall
survival. Considering a VEGF cut-off of 43 pg/ml, an
association of baseline VEGF with clinical response at
week 24 for 157 patients treated ipilimumab was evi-
denced (p = 0.019). As a result, ipilimumab was tested
in association with bevacizumab in a phase 1 clinical
trial. Patients were divided in different cohorts: cohort
1: 10 mg/kg ipilimumab plus 7.5 mg/kg bevacizumab,
cohort 2: 10 mg/kg ipilimumab plus 15 mg/kg bevacizu-
mab (dose expansion), cohort 3: 3 mg/kg ipilimumab plus
7.5 mg/kg bevacizumab, cohort 4: 3 mg/kg ipilimumab
plus 15 mg/kg bevacizumab with the induction phase
every 3 weeks × 4 cycles and the maintenance phase of
bevacizumab continued every 3 weeks, and ipilimumab
continued every 3 months. Grade >3 toxicities included
hypertension, giant cell (temporal) arteritis, hepatitis
and bilateral uveitis/retinitis. Best objective response
rate (BORR) (Complete Response and Partial responses)
resulted in 17.4% and durable stable disease (≥6 months)
were observed in 50% of the patients. At maximum toler-
ated dose (MTD) Complete Response/Partial responses
were 35.3% and durable Stable Disease (≥6 months)
resulted in 53% of patients (analysis of 17 patients).
Median follow up time was 17.3 months. Median PFS
was 9.0 months, 95% CI (5.5 to 14.5 months). In the
subgroup analysis, according with the different cohorts,
PFS resulted in C1: 6.4 months, in C2: 14.5 months, in
C3: 6.6 months and in C4: 7.6 months. Median overall
survival resulted 25.1 months, 95% CI (12.7 to ∞). Median
OS for the treatment population including MTD was
25.1 months. There was apparent increase in central
memory phenotypes for both CD4 and CD8 cells with
the addition of bevacizumab not seen to such an extent
with ipilimumab alone.
Morphologic changes in tumor endothelium and blood
vessels in post-treatment biopsies were also observed
as a function of treatment. Endothelia activation was
associated with intense immune cell infiltrates. In pilot
studies to identify potential targets of the immune
responses, Galectin-1 and Galectin-3 were identified.
Galectin-1, −3 and −9 specific antibodies were commonly
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and bevacizumab and frequently increased as function of
treatment. Targeting VEGF can have potential synergies
with CTLA-4 blockade inducing immune mediated vascu-
lopathy, immune modulatory effects of VEGF, decreased
DCs maturation and T cell trafficking. The combination
of ipilimumab and bevacizumab may be an effective
therapy in metastatic melanoma, but it needs further
investigations in randomized phase 2 clinical trials [94].
Tumor microenvironment and biomarkers
Markers that accurately predict responding patients
would be of the greatest clinical utility in all types of
therapy. Once a cancer biomarker has been validated, it
can be used to diagnose, to define disease risk or to tailor
treatments for an individual patient. The identification of
biomarkers for targeted therapy will help clinicians to
stratify patients into molecular subgroups, which facilitate
the selection of therapy. Several studies suggest that
immune-based correlates to an anti-tumor response in
clinical trials of cancer immunotherapy could also be
found. The assays that could define the potency of the
immunomodulatory agent or biomarkers that may dir-
ectly assess immune destruction at the targeted tumor,
thus directly reflecting the anti-tumor response are of
great need. Many candidate biomarkers are worthy of
exploration but they require appropriately powered
specimen cohorts and clinical trials to determine their
clinical utility before they are used in clinic.
Understanding how tumor rejection occurs will help
to optimize existing immunotherapies and develop new
effective anti-cancer therapeutic approaches. Adoptive
cell transfer therapy (ACT) has been a successful approach
to treat melanoma patients. In order to identify factors in
tissue infiltrating lymphocytes (TILs), tumor or the host
that associate with clinical response, TILs from 142 patients
enrolled in five adoptive cell therapy trials, 113 melanoma
metastases and 15 melanoma cell lines derived from the
15 melanoma metastases were analyzed. Gene expression
profiling of TILs selected from patients that achieved a
complete response (CR), a partial response (PR) or lacking
response (NR) after treatment with autologous TILs and
IL-2 demonstrated significant differences in expressed
genes. Specifically, comparison of TILs of patients with
CR to TILs of NR patients identified 61 highly differen-
tially expressed genes including apoptosis-related genes,
chemokine receptors, cytokines and others.
A panel of 113 melanoma metastases from patients with
CR, PR or NR has also been compared by gene expression
and 15 cell lines derived from those metastases using array
Comparative Genomic Hybridization (aCGH) were char-
acterized. Negative correlation between the mRNA level
for nitric oxide synthase 1 (NOS1) and patients response
to ACT therapy was observed. High NOS1 expression alsocorrelated with gene amplification of NOS1 locus in the
segment 12q22-24. NOS1 functional impact on immune
response was further validated in vitro in melanoma cell
lines co-cultured with normal donor PBMC stimulated
with IFNα using STAT1 phosphorylation assay. High
NOS1 producing melanoma cell lines demonstrated sig-
nificant inhibition of pSTAT1 in PBMC suggesting that
NOS1 expression links immune dysfunction in circulating
immune cells with an identifiable genotype of melanoma.
The direct impact of NOS1 was further tested by in vitro
assays using a mimic of NOS1 products Nitric Oxide
(NO) which directly inhibits IFNα signaling [95]. This data
suggest a critical role for NOS1 for melanoma induced
immune suppression and that melanoma cell-derived NO
is a crucial modulator of immune function in the tumor
microenvironment and provides a potentially novel target
for immunotherapy. NOS1 status could also serve as a
potentially predictive biomarker of immune responsive-
ness to adoptive cell therapy.
In addition, to distinct gene expression signature of
TILs associated with complete tumor regression host
genetic factors which might determine predisposition to
tumor response were explored. Interferon Regulatory
Factor (IRF)-5 is a key transcription factor in IFN type I
pathway and is a critical mediator of host immunity.
IRF-5 signaling plays important role in development of
systemic lupus erythromatosus (SLE) autoimmunity by
inducing apoptosis, and up-regulating inflammatory cy-
tokines (IL-6, IL-12, TNFα, etc.) and IFNα/β secretion.
Polymorphisms in IRF5 resulting in enhanced IRF-5
function have been associated with SLE [96]. Similarly,
polymorphic SNP variants may contribute to the diverse
clinical outcome for cancer patients treated with immu-
notherapy. Genetic polymorphism analysis of IRF-5 in
patients undergoing ACT therapy demonstrated significant
association with clinical outcome. Differences in genetic
variants of IRF-5 in responders vs. non-responders suggest
that IRF-5 genotype may influence immune responsiveness
by affecting the intrinsic biology of melanoma [97].
Extended polymorphism analysis using Genome Wide
Association Study (GWAS) comparing CR vs. NR patients
demonstrated G-protein coupled receptor kinase 5 (GRK5)
polymorphisms to have one of the highest association with
outcome. Several studies have shown a broad role for
GRK5 in cell signaling and it has been proposed to be a
critical kinase in the pathogenesis of several diseases
including cancer. GRK5 has broad role in cell signaling
including its function as a mediator in inflammation.
GRK5 can be a positive regulator of LPS-induced inflam-
matory cytokine and chemokine production in vivo via
IkBα-NFκB signaling pathway. Both IκBα phosphorylation
and gene expression were significantly inhibited in the
GRK5 knock out (KO) mice compared to the wild type
(WT mice). In addition, inflammatory response, and
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cient mice. GRK5 and another kinase in the GRK family
GRK6 regulate Wnt/β-catenin signaling by phosphorylat-
ing low density lipoprotein receptor-related protein 6
(LRP6). Phosphorylation of TP53/p53 by GRK5 inhibits
TP53/p53-mediated apoptosis and phosphorylation of
adaptor protein ST13 controls internalization of the
chemokine receptors (CCR3, CXCR2, 4 and 6). Together,
the data implicate GRK5 as an important molecular target
in melanoma.
Environmental factors such as gut commensal bacteria
and their immune regulatory function in anti-cancer
immune response were explored in animal model. Experi-
mental evidence in models of autoimmunity and infection
indicated that systemic innate and adaptive immune
responses are influenced by gut commensal bacteria
and they are impaired by treatment with antibiotics. In
mouse model, SC transplanted tumor responded to anti-
IL-10R antibody administration following intratumoral
CpG treatment resulting in tumor rejection. However,
pre-treatment with antibiotic (vancomycin, imipenem,
and neomycin) to create bacterial free gut abrogated
efficacy of anti-IL-10R antibody and CpG treatment [98].
This data provide evidence that intestinal bacteria can
influence the inflammatory and anti-tumor response.
In summary, tumor rejection remains a multifactorial
phenomenon and involves the genetic, epigenetic, pheno-
typic characteristics of cancer cells, immune cells, host
factors as well as an environment. Understanding these
interactions might have implications for classification
of patient for specific therapies.
Tumor cells use different mechanisms to escape immune
recognition including antigen/MHC loss, expression of
ligands for inhibitory T cell receptors on the tumor sur-
face (e.g., PD-L1), and secretion of immunosuppressive
cytokines among others [99,100]. The assessment of the
immune/inflammatory infiltrates in the tumor bed could
help to predict the responsiveness to immune modulating
therapies, such as adoptive-cell-transfer therapy (ACT)
with tumor-infiltrating lymphocytes (TILs). TILs are
generated from the in vitro culture of tumor cells digests
derived from the tumor followed by in vitro expansion. In
most clinical trials, the measure of anti-tumor activity of
the expanded TILs before infusion into the patient is
secretion of IFNγ. Pretreatment lymphodepletion based
on either a round of chemotherapy or on whole-body
radiation is used to increase the success of ACT therapy.
An experimental approach to generate TILs involves
two phases. The first phase encompasses the initial isola-
tion of TILs from fresh tumor specimens and expansion
with high dose of IL-2. Specifically, tumors were minced
into fragments, digested with triple enzymes mixture of
collagenase, hyaluronidase and DNase, and resulting
cell suspension was washed and cells were counted.Cultures of 106 cells (Tumor plus T cells)/2 ml/well in
a 24 well plates were established (RPMI-1640, Human
AB serum plus 6000 IU/ml IL-2) and cells were cultured
for 3 – 8 weeks. In the second phase cell cultures are
scaled up to generate the final infusion product. After the
initial outgrowth T cells were co-cultured alone (negative
control), with immobilized anti-CD3 (positive control)
or with feeder cells that were either autologous tumor
cells or unrelated melanoma tumor cell lines (specificity
control). Quantitative IFNγ release assay was used to
determine TILs effector function. The results of culturing
a cohort of 36 TIL cultures were as follows [Bifulco et al.
in progress]. Approximately half of TIL cultures were
successfully grown and demonstrated tumor–specificity.
A quarter of TIL cultures were established but they did
not secrete IFNγ in response to specific tumor stimula-
tion. Another quarter of cell cultures failed to grow.
Despite the success of ACT therapy in achieving a
clinical response rate the degree of successful culture of
TILs and the response among patients can greatly vary
among patients. Pilot studies demonstrated promising
results with this treatment approach but there are both
scientific and logistic challenges to overcome to expand-
ing the use of this therapy in clinic. Not all metastatic
melanoma patients who have their tumor surgically
resected are eligible for TIL therapy, as the TILs from
their tumors cannot be successfully grown and expanded
to sufficient numbers or lack tumor-specific function.
Some patients may have T cells that have lost potency or
the ability to proliferate and function poorly. Predictive
biomarkers, which could be used to predict whether a
tumor from a given patient will yield successfully growing
TIL culture for therapy, are needed. For example, the total
number and TILs composition, including the frequency of
CD8 vs. CD4 T cells could have an impact on in vitro
growth and the clinical response of ACT. The expression
of a number of markers including CD27, CD28, CCR7,
CD62L, CD45RA/RO, CD25 and 4-1BB/CD137 by T cells
has been indicated to correlate with T-cell differentiation
and activation and response. Chemokine signature, im-
mune effector function markers and immunosuppressive
factors might be important to better define the phenotypic
state and competency of T cells for TILs therapy.
Immunohistochemistry (IHC) is a useful method that
allows for a detailed evaluation of the tumor in situ and its
microenvironment, including the composition of immune
cell infiltrate and the pattern of distribution of infiltrating
TILs (intratumoral vs. peritumoral infiltration). If properly
validated, IHC analysis could enable identification of
potential biomarkers that correlate with clinical out-
come of ACT treated patients. Histological analysis of
the formalin fixed and paraffin embedded (FFPE) tumor
blocks from synchronous and metachronous melanoma
biopsy was carried to evaluate the inflammatory/immune
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of images.
The data suggest that 50% of failures to grow tumor-
specific TILs are associated with the presence of a MDSC
rich microenvironment (Low CD8, High CD163, and High
MPO). The presence of increased numbers of Tregs and
MDSCs that are major components of the immune
suppressive microenvironment could promote T cell
dysfunction. These cells might suppress T cell activation
by multiple mechanisms, including uptake of essential
amino acids for T cell activation like arginine and/or
cysteine. Preliminary data suggests that the ratio between
T effector cells and suppressor cells in the tumor may be
indicative of the successful/unsuccessful TILs culture.
However, no clear criteria and the cutoff value for the
density of suppressor cells were identified. Lack of cor-
relation between cellular components and the growth
success rates suggests other factors that might predict
the success rate in growing TILs. Secretion of immu-
nosuppressive molecules like TGFβ has also been impli-
cated in suppressive function of myeloid cells. Other
immunosuppressive factors such as the enzyme indola-
mine deoxygenase (IDO) and PD-L1 expression might
contribute to a negative feedback mechanism in the
tumor microenvironment.
Further studies are needed to characterize multiple
metachronous metastases from patients for who TIL
cultures cannot be established and compare with TIL
cultures that have been successfully grown. These data
might help to understand the mechanisms involved in
the microenvironment that are conducive to the in vitro
growth of tumor-specific TILs. The set of markers to
identify such factors including a myeloid-enriched/T
effector-poor microenvironment might help to identify
patients with increased likelihood to establish tumor-
specific TILs for ACT therapy. This information might
also be used to develop strategies to pre-treat patients in
order to augment conditions that improve recovery of
tumor-specific T cells.
Over the last few years, several newly developed
immune-based cancer therapies including anti-CTLA-4,
anti-PD-1/PD-L1 as well as IFNα have been shown to
induce clinical responses in significant numbers of patients.
As a result, there is a need to identify immune biomarkers
capable of predicting clinical response.
IL-2 and sIL-2R (sCD25) seem to have a role in anti-
CTLA-4 monoclonal antibody efficacy. IL-2/IL-2Rβ-
dependent efficacy of ipilimumab has been demon-
strated in mice model. Blocking IL-2Rβ, ipilimumab
efficacy improves in mice implying that sCD25 can be
considered a decoy receptor with immunosuppressive
functions. Furthermore, data from the analysis of 272
patients with metastatic melanoma from 9 cohorts of
patients showed that sCD25high combined with LDHhighlevels predict resistance to ipilimumab [Zitvogel et al.,
submitted].
A phase 1 trial studied clinical activity, safety and
biomarkers of PD-L1 blockade with an engineered anti-
PD-L1 antibody (MPDL3280A) in non-small cell lung
cancer (NSCLC). Additional analyses from a clinical
studies showed that PD-L1 is broadly expressed in NSCLC,
with a prevalence of about 45% in adenocarcinomas and
50% in squamous cell carcinomas. In the ongoing phase 1a
trial with MPDL3280A MAb that was administered IV
every 3 weeks for up to 16 cycles in patients affected by
metastatic solid tumors; patients were stratified according
with PD-L1 status. The treatment resulted in ORR in 23%
patients with 17% SD longer than 24 weeks and 24 weeks
PFS in 45% of NSCLC patients.
Correlation between best response and PD-L1 expres-
sion in tumor tissue using IHC was observed. In tumors
with PD-L1 level at IHC score 3 (≥10% tumor immune
cells positive for PD-L1) ORR resulted in 83% of patients
(5/6), while in patients with an IHC score of 2 and 3
(≥5% tumor immune cells positive for PD-L1) ORR was
46% (6/13). ORR was 31% in patients with a PD-L1 IHC
score 1, 2 (≥1% tumor immune cells positive for PD-L1).
These data show that PD-L1 expression as measured by
immunohistochemistry suggested a correlation between
pretreatment tumor PD-L1 expression and clinical response
to anti-PD-L1 monotherapy [101]. Pre-treatment levels of
PD-L1 expression were also associated with increased likeli-
hood of response to nivolumab monotherapy in advanced
melanoma, although some responses were also observed
independent of PD-L1status including negative patients.
However, PD-L1 expression did not correlate with response
for the concurrent regimen of nivolumab and ipilimumab.
Markers predicting response to anti-CTLA-4 are not well
defined but absolute lymphocyte count (ALC), immune-
related adverse events (irAE), NY-ESO1 expression, and
sCD25 have been implicated in several studies. A rise of
the ALC during-treatment was associated with favorable
response to ipilimumab monotherapy but no correlation
between responses to nivolumab monotherapy or ipilimu-
mab and nivolumab combination therapy and response
and ALC status was seen.
Ulceration can be considered a biomarker of IFN
sensitivity. Ulcerated melanoma can be considered as
a tumor with distinct biology because it correlates
with much lower survival for the tumors adjusted to
Breslow thickness. Data from 2644 patients enrolled in
the IFN adjuvant trials EORTC18952 and EOTRC18991
evidenced an HR of 0.75 for RFS, an HR of 0.59 for DMFS
and an HR of 0.58 for OS in patients with ulcerated
melanoma. Long term follow-up confirmed the survival
advantage of IFN therapy in ulcerated melanoma (EORTC
18991). The meta-analysis of individual patients’ data from
randomized trials, performed in 2007, confirmed that the
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observed in ulcerated melanoma. In 2014 at ASCO this
was confirmed in the Individual Patient Data (IPD)-Meta-
analysis of all 15 trials comparing IFN to observation,
in >7500 patients [102].
Thus, IFN can be considered a “targeted therapy” for
ulcerated melanoma patients because only ulcerated mela-
nomas are IFN sensitive (OS HR 0.77), while non-ulcerated
tumors are IFN insensitive (OS HR 0.98). Furthermore, the
stage is important because in stage IIB- III- N1 (Sentinel
Node +) patients HR for OS resulted in 0.60 while stage
III-N2 (Macroscopic/Palpable Node +) HR for OS was
0.85. Preliminary results of a molecular signature showed
that 6 miRNAs emerge in ulcerated patients with IFN
therapy that did not relapse. Identification of predictive
markers of response would be valuable to guide effective
use of immunotherapies.
Expression of a subset of chemokine genes is associated
with presence of CD8+ T cells in melanoma metastases,
and a transcriptional profile encompassing expression
of these genes appears to identify patients with clinical
benefit from immunotherapies. Two immunologic sub-
types of melanoma based on tumor microenvironment
have been described: T cell rich/inflamed, expressing
chemokines, CD8+ T cells, and a type I IFN signature;
and T cell poor/non-inflamed, with lack of chemokines
for T cell recruitment and low indicators of inflam-
mation [103]. These two immunologic subtypes have
different mechanisms of resistance. T cell rich/inflamed
uses immune inhibitory pathways, while T cell poor/
non-inflamed uses immune exclusion as a major mech-
anism of resistance [104].
Immune inhibitory mechanisms dominating in CD8+ T
cell-infiltrated melanomas are PD-L1 (engages PD-1 on
activated T cells), IDO (indoleamine-2, 3-dioxygenase;
degrades tryptophan), CD4+CD25+FoxP3+Tregs (extrinsic
suppression) and T cell anergy (T cell intrinsic dysfunction).
In fact, the presence of Tregs and expression of PD-L1
and IDO are associated with a CD8+ T cell infiltrate and
these factors are part of an immune-intrinsic negative
feedback loop [105].
Another mechanism of resistance is T cell-intrinsic
dysfunction (anergy). CD8+ TILs that co-express LAG3,
PD-1, and 4-1BB or cytotoxic and regulatory T cell
molecule (CRTAM) are defective at IL-2 production.
They also show defective proliferation and blocked
RAS pathway activation. However, these dysfunctional
T cells still make IFNγ and Tregs-recruiting chemokines
(CCL1, CCL22), arguing that they may themselves have
immune regulatory properties. Most of the tumor Ag-
specific T cells fall into this subset. Interventions aimed
at uncoupling negative regulatory mechanisms in T
cell-infiltrated melanomas are under development and
are generating intense interest. These include inhibitoryreceptor blockade with MAbs against PD-1/PD-L1 or
CTLA-4; anergy reversal with combinations of anti-
41BB, anti-LAG3, and/or anti-Tim-3; IDO inhibition
using small molecule inhibitors, and anti-CD25 for Tregs
depletion. Anti-PD-1 MAb in metastatic melanoma gener-
ated a 30% RR in 90 patients treated [106]. In mouse
models, combinatorial targeting of CTLA4 ± PD-L1 ±
IDO results in improved tumor control. Synergistic per-
mutations markedly increase the number of proliferating
IL-2-producing CD8+ T cells in tumor microenvironment
[107]. Combinatorial treatment with anti-CTLA-4 and
anti-PD-1 MAbs also can have profound clinical activity
in metastatic melanoma. Other combinations ongoing or
planned are anti-CTLA-4 plus IDOi phase 1/2, anti-KIR
plus anti-PD-1 phase 1, anti-LAG-3 plus anti-PD-1 phase
1, Vaccine plus anti-CD25, or anti-PD-1 plus IDOi.
The mechanism by which the spontaneous T cell re-
sponse develops against melanoma is being elucidated.
Innate immune sensing of tumors drives host type I
IFN production and cross-priming of CD8+ T cells via
CD8α+/−DCs [108]. Recent evidence suggests that the
innate immune sensing pathway that mediates host
type I IFN production is via the stimulator of inter-
feron genes (STING) pathway [Woo et al., manuscript
submitted]. STING agonists are being developed to
induce de novo inflammation in non-T cell-infiltrated
cancers. DMXAA is a mouse STING agonist, and intratu-
moral DMXAA promoted rejection of B16 melanoma
in a mouse model. DMXAA triggered a potent CD8+ T
cell response against tumor-expressed SIY antigen and
mice that rejected tumors with DMXAA were protected
against a second tumor rechallenge [Corrales et al., manu-
script submitted].
Molecular mechanisms that explain why a subset of
patients develops a spontaneous T cell infiltrate while
another major subset does not are being pursued via three
major hypotheses: 1) Germline genetic differences at the
level of the host (polymorphisms in immune regulatory
genes, e.g. in type I IFN and STING pathways); 2) Somatic
differences at the level of tumor cells (distinct oncogene
pathways activated in different patients or mutational
landscape and antigenic repertoire); and 3) Environmental
differences (intestinal microbiome /immunologic/patho-
gen exposure history of patients). Logical combination
therapies are being pursued clinically that are highly antic-
ipated to show improved efficacy.
In the treatment of metastatic melanoma, mutant
BRAFV600E can be targeted with selective BRAF inhibitors
(BRAFi) such as vemurafenib and dabrafenib. Although
initial response rates are high, tumors eventually become
resistant and progress [109]. Anti-CTLA-4 and anti-PD-1
antibodies, however, can induce durable responses in a
small subgroup of melanoma patients [110,111]. Combin-
ing selective BRAFi and immunotherapies could prove
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agents [112]. To persuade combinations of immunother-
apies and selective BRAFi, the immunological conse-
quences of selective BRAFi treatment need to be explored.
Selective BRAFi might support anti-tumor immunity
directly or indirectly by disarming immunosuppressive
factors such as MDSC. MDSC are a heterogeneous
population of myeloid cells that able to suppress innate and
adaptive immunity by various mechanisms. Accumulation
of MDSC has been described in patients with different ma-
lignant tumors including melanoma [113]. In peripheral
blood mononuclear cells (PBMC) from patients with ad-
vanced melanoma, two phenotypically distinct MDSC sub-
sets were recently described: monocytic (mo)MDSC which
are CD45+Lin−HLA-DR-/lowCD14+CD15dim CD66b−CD33+
CD11b+Arginase1−CD16-/low and granulocytic (gr)MDSC
which are CD45+Lin−HLA-DR−CD14−CD15+CD66b+
CD33+CD11b+Arginase1+CD16-/low [114]. A significant
increase in the frequency of both subsets was found in
patients witch advanced melanoma as compared to
healthy donors and patients with localized disease [114].
In patients responding to vemurafenib, tumor-related
accumulation of both subsets was reversed. In vitro,
vemurafenib decreased the ability of melanoma cell lines
to induce moMDSC. While these findings indicate a bene-
ficial role of vemurafenib in anti-tumor immunity, the
effector phase of the anti-tumor response needs to be
considered, too. In vitro, analogues of vemurafenib do not
inhibit human lymphocyte function [115]. Recognition
and cytotoxicity against melanoma cell lines by T cells
specific for melanoma differentiation antigens (MDA) was
increased by selective BRAFi treatment, that up-regulated
MDA expression [115].
Analysis of tumor biopsies obtained during treatment
with dabrafenib or vemurafenib also showed an enhanced
MDA expression [116] and an increased infiltration of
melanoma metastases by human CD4+ and CD8+ T cells,
the latter associated with the reduction of tumor mass.
Composition and functionality of patients’ lymphocytes
remained unaffected with dabrafenib treatment [117].
Numbers of circulating T, B and NK cells did not change
and ex vivo memory responses by CD4+ and CD8+ T cells
to recall antigens were not impaired by treatment with
dabrafenib. In summary, lymphocyte function seems to be
unaffected by selective BRAFi while antigenicity of melan-
oma cells is increased. Recently, the first comprehensive,
immunological study of vemurafenib and dabrafenib has
been performed [118].
Surprisingly, vemurafenib but not dabrafenib decreases
the number of peripheral lymphocytes in melanoma
patients. Loss of lymphocytes was found to be associated
with treatment rather than disease progression and did not
predict survival in patients treated with selective BRAFi.
Loss of peripheral lymphocytes was also independentfrom pre-treatment LDH value. Further analyses of
lymphocyte subpopulations showed that CD4+ T cells, but
not CD8+ T cells or B cells were decreased significantly
during vemurafenib treatment while an increase of circu-
lating NK cells can be observed. Phenotypically, a shift
toward a naïve phenotype was observed within CD4+ T
cells compared to pre-treatment samples. Also, CD4+ T
cells isolated from samples obtained during vemurafenib
treatment showed a decreased ability to secrete INFγ and
IL-9. Thus, vemurafenib causes a selective loss of CD4+
T cells and changes the composition and impairs the
function of peripheral CD4+ T cells. Vemurafenib increases
the frequency of naive but decreases the frequency of
central memory CD4+ T cells and decreases the ability of
CD4+ T cells to secrete IL-9 and IFNγ when analyzed
ex vivo [118]. These findings indicate a different impact of
vemufafenib and dabrafenib on the human immune sys-
tem which is supported by recently presented clinical data.
While a phase 1 trial employing vemurafenib in combin-
ation with ipilimumab had to be discontinued due to liver
toxicity, such toxicity was not observed when dabrafenib
was given concomitant to ipilimumab [119]. Taken to-
gether, these clinical and translational findings indicate
that different selective BRAFi can show a distinct impact
on the human immune systems which needs to be consid-
ered, in particular when planning combinations of select-
ive BRAFi and immunotherapies.
For the physician treating patients with completely
resected stage II/III melanoma, a dilemma is how to
advise the patient and whether to prescribe interferon or
an experimental treatment. The key question is whether
micrometastases, formed before the tumor was surgically
removed, are present and able to grow and expand. This
can be influenced by tumor intrinsic factors (oncogenes,
cell type of origin or location of primary tumor) and
host factors (tumor micro-environment and the immune
system). Immune surveillance controls dormant tumors
and, in melanoma, CD3 count and TILs correlate with
improved survival in stage IIIA-IVA disease [120]. Further,
the immunoscore and immune profiling is prognostic in
multiple tumor types [121]. However, RNA profiling has
been challenging in primary melanoma tumors because
clinical standards dictate that the entire tumor be FFPE,
making it difficult to isolate high quality RNA [122].
NanoString is a probe-based technology specifically de-
signed to quantify mRNA transcripts in partially degraded
RNA [123]. Using NanoString, we quantified mRNA copy
number for 446 genes selected using a hypothesis driven
approach based on literature review in a training set of
primary tumors (n = 40) [124]. NanoString results were
confirmed by immunohistochemistry. Based on this
data, using linear regression models, we defined a 53-
immune gene panel correlating with recurrence free
and disease specific survival in the training set. This
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population (n = 48). These 53-genes have high overlap
with a co-expression network identified using unbiased
methods using expression data available in GEO, Gene
Expression Omnibus (GEO), a public functional genomics
data repository supporting MIAME-compliant data sub-
missions. Key nodes in a Baysian network defined using
the GEO expression data identify Th1 processes, TCR and
BCR activation, and CD2 as critical modulatory pathways.
Protein levels of CD2 measured by IHC were also found
to correlate with non-progression and prolonged survival.
Analysis of immune gene expression in primary melan-
oma tumors is likely to yield valuable biomarkers and the
proposed 53-gene panel should be studied prospectively
in larger studies.
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